US20030036517A1 - Nucleic acid mediated rna tagging and rna revision - Google Patents
Nucleic acid mediated rna tagging and rna revision Download PDFInfo
- Publication number
- US20030036517A1 US20030036517A1 US09/205,520 US20552098A US2003036517A1 US 20030036517 A1 US20030036517 A1 US 20030036517A1 US 20552098 A US20552098 A US 20552098A US 2003036517 A1 US2003036517 A1 US 2003036517A1
- Authority
- US
- United States
- Prior art keywords
- nucleic acid
- splicing
- trans
- globin
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 170
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 163
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 163
- 230000001404 mediated effect Effects 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 44
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 150
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims description 66
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims description 66
- 108090000623 proteins and genes Proteins 0.000 claims description 58
- 238000006243 chemical reaction Methods 0.000 claims description 50
- 230000002255 enzymatic effect Effects 0.000 claims description 42
- 239000000758 substrate Substances 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 19
- 108091005886 Hemoglobin subunit gamma Proteins 0.000 claims description 18
- 102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 18
- 230000035772 mutation Effects 0.000 claims description 16
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
- 235000018102 proteins Nutrition 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 230000003993 interaction Effects 0.000 claims description 9
- 150000002632 lipids Chemical class 0.000 claims description 9
- 108091027874 Group I catalytic intron Proteins 0.000 claims description 8
- 230000000692 anti-sense effect Effects 0.000 claims description 8
- 108091029499 Group II intron Proteins 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 7
- 235000020958 biotin Nutrition 0.000 claims description 7
- 239000011616 biotin Substances 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 108091092236 Chimeric RNA Proteins 0.000 claims description 4
- 102000015097 RNA Splicing Factors Human genes 0.000 claims description 4
- 108010039259 RNA Splicing Factors Proteins 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 108060003196 globin Proteins 0.000 abstract description 11
- 108091092562 ribozyme Proteins 0.000 description 131
- 108090000994 Catalytic RNA Proteins 0.000 description 129
- 102000053642 Catalytic RNA Human genes 0.000 description 129
- 210000004027 cell Anatomy 0.000 description 95
- 125000003729 nucleotide group Chemical group 0.000 description 56
- 239000002773 nucleotide Substances 0.000 description 51
- 238000000338 in vitro Methods 0.000 description 29
- 239000002243 precursor Substances 0.000 description 28
- 210000003743 erythrocyte Anatomy 0.000 description 27
- 230000014509 gene expression Effects 0.000 description 27
- 239000000203 mixture Substances 0.000 description 24
- 239000000047 product Substances 0.000 description 21
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 17
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 210000004700 fetal blood Anatomy 0.000 description 16
- 238000013459 approach Methods 0.000 description 15
- 238000013507 mapping Methods 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 230000003197 catalytic effect Effects 0.000 description 13
- 239000002502 liposome Substances 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 230000003321 amplification Effects 0.000 description 12
- 238000003776 cleavage reaction Methods 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 238000003199 nucleic acid amplification method Methods 0.000 description 12
- 230000007017 scission Effects 0.000 description 12
- 230000008439 repair process Effects 0.000 description 11
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 10
- 108700026244 Open Reading Frames Proteins 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 102000018146 globin Human genes 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000001415 gene therapy Methods 0.000 description 9
- 239000013614 RNA sample Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000011886 peripheral blood Substances 0.000 description 8
- 210000005259 peripheral blood Anatomy 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 238000010839 reverse transcription Methods 0.000 description 8
- 208000007056 sickle cell anemia Diseases 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 208000026350 Inborn Genetic disease Diseases 0.000 description 7
- 238000002123 RNA extraction Methods 0.000 description 7
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 208000016361 genetic disease Diseases 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 7
- 229940045145 uridine Drugs 0.000 description 7
- 108700024394 Exon Proteins 0.000 description 6
- 101710163270 Nuclease Proteins 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 101150066555 lacZ gene Proteins 0.000 description 6
- -1 nucleozyme Proteins 0.000 description 6
- 108700025694 p53 Genes Proteins 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 108091092195 Intron Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 239000003377 acid catalyst Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000005026 transcription initiation Effects 0.000 description 5
- 230000005030 transcription termination Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000295146 Gallionellaceae Species 0.000 description 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- 108010066717 Q beta Replicase Proteins 0.000 description 4
- 238000010240 RT-PCR analysis Methods 0.000 description 4
- 241000223892 Tetrahymena Species 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000011536 extraction buffer Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 210000001324 spliceosome Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 3
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 3
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000982 GIR1 ribozyme Proteins 0.000 description 3
- 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000925 erythroid effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- 108091027757 Deoxyribozyme Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000028782 Hereditary disease Diseases 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000002869 anti-sickling effect Effects 0.000 description 2
- 229940124574 antisickling agent Drugs 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 108700014844 flt3 ligand Proteins 0.000 description 2
- 108010038853 gamma-Globins Proteins 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 230000010309 neoplastic transformation Effects 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000008196 pharmacological composition Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 229940095696 soap product Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- LKUDPHPHKOZXCD-UHFFFAOYSA-N 1,3,5-trimethoxybenzene Chemical compound COC1=CC(OC)=CC(OC)=C1 LKUDPHPHKOZXCD-UHFFFAOYSA-N 0.000 description 1
- SGKGZYGMLGVQHP-ZOQUXTDFSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-methylpyrimidine-2,4-dione Chemical compound CC1=CC(=O)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SGKGZYGMLGVQHP-ZOQUXTDFSA-N 0.000 description 1
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 1
- 108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VPLZGVOSFFCKFC-UHFFFAOYSA-N 3-methyluracil Chemical compound CN1C(=O)C=CNC1=O VPLZGVOSFFCKFC-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 208000022305 Double heterozygous sickling disease Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010063774 E2F1 Transcription Factor Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 108010093099 Endoribonucleases Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 108010044495 Fetal Hemoglobin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000009336 Hemoglobin SC Disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- ULEBESPCVWBNIF-BYPYZUCNSA-N L-arginine amide Chemical compound NC(=O)[C@@H](N)CCCNC(N)=N ULEBESPCVWBNIF-BYPYZUCNSA-N 0.000 description 1
- 108090000004 Leadzyme Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 101100391171 Schizosaccharomyces pombe (strain 972 / ATCC 24843) for3 gene Proteins 0.000 description 1
- 108010016797 Sickle Hemoglobin Proteins 0.000 description 1
- 208000000859 Sickle cell trait Diseases 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 239000012163 TRI reagent Substances 0.000 description 1
- 241000248384 Tetrahymena thermophila Species 0.000 description 1
- 102100024026 Transcription factor E2F1 Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108091034131 VA RNA Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010817 Wright-Giemsa staining Methods 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/124—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes based on group I or II introns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/124—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes based on group I or II introns
- C12N2310/1241—Tetrahymena
Definitions
- This invention relates to method and reagent for tagging nucleic acid molecules and repairing RNA molecules.
- Ribozyme mediated trans-splicing In addition to performing self-splicing, the group I ribozyme from Tetrahymena can trans-splice an exon attached to its 3′ end onto a separate 5′ exon RNA (FIG. 1B). In this reaction, the 5′ exon is not covalently attached to the ribozyme but is bound via base pairing through the 5′ exon binding site on the ribozyme. In the process of pairing, a U is positioned across from the guanosine present at the 5′ end of the 5′ exon binding site.
- the ribozyme cleaves the bound substrate RNA at the reconstructed 5′ splice site and ligates its 3′ exon onto the 5′ exon cleavage product (FIG. 1B).
- Trans-splicing by group I ribozymes is extremely malleable. Virtually any U residue in a 5′ exon can be targeted for splicing by altering the nucleotide composition of the 5′ exon binding site on the ribozyme to make it complementary to a target sequence present on the substrate RNA. Because no specific 3′ exon sequences are required, virtually any 3′ exon sequence can be spliced onto a targeted U residue by such a reaction.
- trans-splicing ribozyme can be employed to revise the sequence of targeted RNAs.
- a trans-splicing group I ribozyme from Tetrahymena can be employed to repair truncated lacZ transcripts (Sullenger et al., 1994, Nature 371, 619; Sullenger et al., U.S. Pat. No. 5,667,969; both are incorporated by reference herein).
- a 3′ exon sequence encoding the restorative lacZ sequence was attached to the splicing ribozyme.
- the ribozyme For trans-splicing to correct the defective lacZ messages, the ribozyme must recognize the truncated 5′ lacZ transcript by base pairing, cleave off additional nucleotides, hold onto the 5′ lacZ cleavage product, and ligate the restorative lacZ 3′ exon sequence onto the cleaved 5′ product to yield the proper open reading frame for translation. It was shown that the ribozyme could faithfully accomplish such RNA revision both in vitro and in Escherchia coli . Furthermore, in E. coli the repaired RNAs went on to be translated to produce a functional enzyme.
- Haseloff et al. U.S. Pat. No. 5,641,673 describe a method of “cell ablation . . . that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing group I trans-splicing ribozyme.”
- This invention features a method in which a mutant beta-globin transcripts are altered by use of a splicing reaction in vivo or in vitro. It involves the manipulation of genetic information to ensure that a useful transcript is provided within a cellular system or extract.
- the invention also features a method of identifying regions in a target RNA that are accessible to interaction with separate macromolecules such as nucleic acid molecules, using trans-splicing nucleic acid molecules.
- the invention further describes a method of attaching non-nucleic acid Tags to target nucleic acid molecules.
- the trans-splicing nucleic acid molecules are enzymatic nucleic acid molecules. More specifically the trans-splicing nucleic acid molecules are derived from group I (Sullenger et al., supra) or group II introns (Jacquier, 1990, TIBS 15, 351; Michels et al., 1995, Biochemistry, 34, 2965; Chanfreau et al., 1994, Science, 266, 1383; Mueller et al., 1993, Science, 261, 1035; Jarrell et al., U.S. Pat. No. 5,498,531; all are incorporated herein by reference).
- group I Sullenger et al., supra
- group II introns Jacquier, 1990, TIBS 15, 351; Michels et al., 1995, Biochemistry, 34, 2965; Chanfreau et al., 1994, Science, 266, 1383; Mueller et al., 1993, Science, 261, 1035; Jarrell e
- the trans-splicing nucleic acid molecules facilitate trans-splicing reaction in the presence of one or more cellular factors, such as protein factors (Bruzik et al., supra; Jarrell supra; Ghetti et al., 1995, Proc. Natl. Acad. Sci., 92, 11461; all are incorporated by reference herein).
- protein factors such as protein factors (Bruzik et al., supra; Jarrell supra; Ghetti et al., 1995, Proc. Natl. Acad. Sci., 92, 11461; all are incorporated by reference herein).
- trans-splicing nucleic acid molecules are derived from pre-messenger RNA introns, but can also be derived from other introns such as group I and group II.
- the invention features a method of replacing a region of a mutant beta-globin RNA molecule containing one or more mutations with a desired beta-globin sequence using trans-splicing nucleic acid molecules, to generate a beta-globin RNA molecule able to express a protein with normal beta-globin protein attributes (FIG. 2A).
- the method involves: a) contacting the target RNA molecule (e.g., mutant beta-globin RNA) in vitro or in vivo with a trans-splicing nucleic acid molecule (e.g.
- the trans-splicing nucleic acid molecule is incubated with the target RNA molecule under conditions suitable for trans-splicing reaction to occur; the trans-splicing reaction removes the defective (mutant) region of the beta-globin RNA and in its place covalently attaches the desired beta-globin sequence in the target RNA molecule.
- beta-globin sequence is meant sequence of beta-globin RNA that does not have mutations that are deleterious to the normal function of a wild type beta-globin protein (see Andrin et al., 1994, Biochem. Cell. Bio. 72, 377; Orkin, 1990, Cell, 63, 665).
- normal beta-globin protein attributes function or properties of a beta-globin protein that are not associated with a disease or a condition (see Andrin et al., 1994, Biochem. Cell. Bio. 72, 377; Orkin, 1990, Cell, 63, 665).
- the invention features a method of converting mutant beta-globin RNA molecule containing one or more mutations into a chimeric beta-gamma-globin sequence using trans-splicing nucleic acid molecules, to generate a RNA molecule able to express a protein with normal gamma-globin protein fuction and properties.
- the method involves: a) contacting the target RNA molecule (e.g., mutant beta-globin RNA) in vitro or in vivo with a trans-splicing nucleic acid molecule (e.g.
- the trans-splicing nucleic acid molecule is incubated with the target RNA molecule under conditions suitable for trans-splicing reaction to occur; the trans-splicing reaction removes the defective (mutant) region of the beta-globin RNA and in its place covalently attaches the gamma-globin sequence in the target RNA molecule to generate a chimeric beta-gamma-globin RNA.
- chimeric beta-gamma-globin sequence is meant a gamma-globin sequence having one or more regions of beta-globin RNA and where the chimeric sequence is able to express a protein having the function and one or more properties of a gamma globin protein (see Andrin et al., 1994, Biochem. Cell. Bio. 72, 377; Orkin, 1990, Cell, 63, 665).
- the trans-splicing nucleic acid molecule is not naturally associated with the Tag sequence since it is not generally desired to splice the Tag sequence of a naturally occurring nucleic acid molecule with a target RNA molecule. Rather, the Tag sequence is chosen or selected to have a desired function once spliced with the target nucleic acid molecule.
- the catalytic nucleic acid molecule is able to cleave and splice, e.g., it has a group I (Sullenger et al., supra) or group II intron (Jacquier, 1990, TIBS 15, 351; Michels et al., 1995, Biochemistry, 34, 2965; Chanfreau et al., 1994, Science, 266, 1383; Mueller et al., 1993, Science, 261, 1035; Jarrell et al., U.S. Pat. No. 5,498,531; all are incorporated herein by reference) motif; the method is performed in vitro or in vivo with an RNA target; and the method can be used to treat genetic disease in a gene therapy type manner, for example, by correcting an abnormal transcript.
- group I Sullenger et al., supra
- group II intron Jacquier, 1990, TIBS 15, 351; Michels et al., 1995, Biochemistry, 34, 29
- the invention features catalytic nucleic acid molecules having a desired Tag sequence as a 3′ exon encoding at least a portion of a useful gene which can be used in gene therapy.
- the Tag sequence can also be attached to a target RNA (for example associated with a certain disease condition) in a biological sample, for example from a patient for diagnostic purposes; the Tag sequence is used as an indicator of the presence and quantity of the target RNA in a sample.
- a target RNA for example associated with a certain disease condition
- Such a molecule can be spliced with and thereby correct or modify the expression of other target RNA molecules.
- the invention also features vectors encoding such catalytic nucleic acid molecules.
- the invention features a method of identifying a region or regions in a target RNA molecule that is accessible to interaction (e.g., hybridization) with a separate nucleic acid molecule involving: a) contacting the target RNA molecule in vitro or in vivo with an enzymatic nucleic acid molecule with trans-splicing activity (e.g.
- group I intron ribozyme comprising a Tag with a defined sequence
- the enzymatic nucleic acid molecule is incubated with the target RNA molecule under conditions suitable for trans-splicing reaction to occur; the trans-splicing reaction covalently attaches the Tag sequence to the target RNA molecule to form a chimeric RNA molecule; and c) identifying the accessible region in the target RNA; the region of target RNA molecule where the Tag sequence has been inserted (accessible region) is readily identified using standard molecular biology techniques such as reverse transcription and polymerase chain reaction.
- the invention features a method of identifying a region or regions in a target RNA molecule that is accessible to interaction (e.g., hybridization) with a separate nucleic acid molecule including the step of contacting the target RNA molecule in vitro or in vivo with an enzymatic nucleic acid molecule with trans-splicing activity (e.g. group I intron ribozyme, group II intron ribozyme or the like), comprising a Tag with a defined sequence.
- the enzymatic nucleic acid molecule includes a target binding domain and an enzymatic domain, where the target binding domain has a randomized region.
- the enzymatic nucleic acid molecule with randomized binding arm is contacted with target RNA molecule under conditions suitable for the attachment of the Tag sequence to the target RNA.
- the region of the target RNA with the inserted Tag sequence is identified readily using standard molecular biology techniques.
- randomized region is meant a region of completely random sequence and/or partially random sequence.
- completely random sequence is meant a sequence wherein theoretically there is equal representation of A, U, G and C nucleotides or modified derivatives thereof, at each position in the sequence.
- partially random sequence is meant a sequence wherein there is an unequal representation of A, U, G and C nucleotides or modified derivatives thereof, at each position in the sequence.
- a partially random sequence can therefore have one or more positions of complete randomness and one or more positions with defined nucleotides.
- nucleic acid molecule capable of interacting with a target nucleic acid molecule and modulate the expression and/or function of the target nucleic acid molecule.
- separate nucleic acid molecules include enzymatic nucleic acid molecules, antisense oligonucleotides, triplex forming oligonucleotides, peptide nucleic acid molecules, aptamers, 2-5 A antisense chimeras, and others.
- antisense oligonucleotide it is meant a non-enzymatic nucleic acid molecule that binds to target RNA by means of RNA-RNA or RNA-DNA or RNA-PNA (protein nucleic acid; Egholm et al., 1993 Nature 365, 566) interactions and alters the activity of the target RNA (for a review see Stein and Cheng, 1993 Science 261, 1004; Agrawal et al., U.S. Pat. No. 5,591,721; Agrawal, U.S. Pat. No. 5,652,356).
- RNA-RNA or RNA-DNA or RNA-PNA protein nucleic acid
- 2-5 A antisense chimera it is meant, an antisense oligonucleotide containing a 5′ phosphorylated 2′-5′-linked adenylate residues. These chimeras bind to target RNA in a sequence-specific manner and activate a cellular 2-5A-dependent ribonuclease which, in turn, cleaves the target RNA (Torrence et al., 1993 Proc. Natl. Acad. Sci. USA 90, 1300).
- TFO triple forming oligonucleotides
- oligonucleotide as used herein is meant a molecule having two or more nucleotides.
- the polynucleotide can be single, double or multiple stranded and may have modified or unmodified nucleotides or non-nucleotides or various mixtures and combinations thereof.
- nucleic acid molecule as used herein is meant a molecule having nucleotides.
- the nucleic acid can be single, double or multiple stranded and may comprise modified or unmodified nucleotides or non-nucleotides or various mixtures and combinations thereof.
- An example of a nucleic acid molecule according to the invention is a gene which encodes for macromolecule such as a protein.
- complementarity as used herein is meant a nucleic acid that can form hydrogen bond(s) with other nucleic acid sequence by either traditional Watson-Crick or other non-traditional types (for example, Hoogsteen type) of base-paired interactions.
- zymatic nucleic acid it is meant a nucleic acid molecule capable of catalyzing reactions including, but not limited to, site-specific cleavage and/or ligation of other nucleic acid molecules, cleavage of peptide and amide bonds, and trans-splicing (see for example (Zaug et al., 324, Nature 429 1986; Cech, 260 JAMA 3030, 1988; Usman & McSwiggen, 1995 Ann. Rep. Med. Chem. 30, 285-294; Christoffersen and Marr, 1995 J. Med. Chem. 38, 2023-2037; all are incorporated by reference herein).
- Such a molecule with endonuclease activity may have complementarity in a substrate binding region to a specified gene target, and also has an enzymatic activity that specifically cleaves RNA or DNA in that target.
- This complementarity functions to allow sufficient hybridization of the enzymatic RNA molecule to the target RNA or DNA to allow the cleavage to occur. 100% complementarity is preferred, but complementarity as low as 50-75% may also be useful in this invention.
- the nucleic acids may be modified at the base, sugar, and/or phosphate groups.
- enzymatic nucleic acid is used interchangeably with phrases such as ribozymes, catalytic RNA, enzymatic RNA, catalytic DNA, catalytic oligonucleotides, nucleozyme, DNAzyme, RNA enzyme, endoribonuclease, endonuclease, minizyme, leadzyme, oligozyme or DNA enzyme. All of these terminologies describe nucleic acid molecules with enzymatic activity.
- enzymatic nucleic acid molecules described in the instant application are not limiting in the invention and those skilled in the art will recognize that all that is important in an enzymatic nucleic acid molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target nucleic acid regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart a nucleic acid cleaving/ligation activity to the molecule.
- enzyme portion or “catalytic domain” is meant that portion/region of the ribozyme necessary for catalytic activity (for example see FIG. 1).
- substrate binding arm or “substrate binding domain” is meant that portion/region of a ribozyme which is complementary to (i e., able to base-pair with) a portion of its substrate. Generally, such complementarity is 100%, but can be less if desired. For example, as few as 10 bases out of 14 may be base-paired. Such arms are shown generally in FIG. 1 and 2 . That is, these arms contain sequences within a ribozyme which are intended to bring ribozyme and target RNA together through complementary base-pairing interactions.
- the ribozyme of the invention may have binding arms that are contiguous or non-contiguous and may be of varying lengths.
- the length of the binding arm(s) are preferably greater than or equal to four nucleotides; specifically 12-100 nucleotides; more specifically 14-24 nucleotides long. If two binding arms are chosen, the design is such that the length of the binding arms are symmetrical (i e., each of the binding arms is of the same length; e.g., five and five nucleotides, six and six nucleotides or seven and seven nucleotides long) or asymmetrical (i.e., the binding arms are of different length; e.g., six and three nucleotides; three and six nucleotides long; four and five nucleotides long; four and six nucleotides long; four and seven nucleotides long; and the like). Those of ordinary skill in the art will recognize that other motifs than those of the group I and group II introns may also be manipulated to provide useful trans-splicing activity.
- the conditions chosen for the contacting step and the trans-splicing step may be those naturally occurring within a cell, or may be manipulated in vitro to ensure that the splicing reaction will occur. These conditions are well known to those in the art, for example, as described by Inoue et al., supra.
- the invention features a method of attaching a Tag moiety other than nucleic acid to a target nucleic acid using enzymatic trans-splicing nucleic acid molecules, comprising the step of contacting the target nucleic acid molecule with the enzymatic trans-splicing nucleic acid molecule comprising a Tag under conditions suitable for the attachment of the Tag.
- Tag sequence is meant a non-naturally occuring sequence with a few nucleotides (10-500 nucleotides) or may be significantly greater and may represent almost all of a molecule encoding a gene product (i.e., at least 1 to 5 kbases).
- Tag is meant a chemical moiety that can be linked to a target nucleic acid molecule using a trans-splicing nucleic acid molecule.
- Non-limiting examples of a Tag are nucleic acid, nucleotides, nucleoside triphosphate, lipid moiety, carbohydrate moiety, biotin, a detergent, peptide, aminoacid, antibiotic, and others.
- the Tag moiety is selected from a group consisiting of a lipid, carbohydrate, vitamin, biotin, a fluoroscence compound (e.g., fluorescein, rhodamine and the like), peptide (e.g., peptides to facilitate intracellular trafficking of nucleic acid molecules), aminoacid, antibody and an antibiotic.
- a fluoroscence compound e.g., fluorescein, rhodamine and the like
- peptide e.g., peptides to facilitate intracellular trafficking of nucleic acid molecules
- aminoacid e.g., peptides to facilitate intracellular trafficking of nucleic acid molecules
- antibody e.g., an antibiotic.
- target nucleic acid molecule any nucleic acid molecule that serve as a target for interaction with a trans-splicing nucleic acid molecule.
- chimeric RNA molecule is one which is a non-naturally occuring not present in the system prior to the initiation and completion of trans-splicing reaction. Alternatively, it may be a completely novel structure which does not occur in nature, but which is useful in gene therapeutic treatment of an organism.
- FIG. 1A is a diagrammatic representation showing splicing reactions of the group I intron from Tetrahymena.
- FIG. 1B shows a schemmatic representation of a strategy for targeted trans-splicing.
- FIG. 2 shows a scheme for ribozyme-mediated repair of sickle beta-globin transcripts.
- X m sickle beta-globin point mutation; ⁇ -3′exon, restorative globin sequence.
- FIG. 3 shows a scheme for identifying accessible regions within beta-globin RNA using trans-splicing ribozyme.
- a library of trans-splicing ribozymes containing randomized guide sequences (5′-GNNNNN-3′) is incubated with beta-globin mRNA.
- Ribozymes in the library that react with accessible uridine residues on beta-globin transcripts attach their 3′ exon Tag to these sites.
- These “Tagged” reaction products are amplified by RT/PCR using a primer (D) specific to the 3′exon Tag and a primer (U) specific for the beta-globin RNA.
- FIG. 4 Trans-splicing a 3 ′ exon Tag onto beta-globin transcripts.
- ⁇ S -61 truncated ⁇ S -globin transcript
- ⁇ S -61 that contains the first 61 nucleotides of the RNA
- ⁇ S -FL the full length ⁇ S -globin transcript
- SC RNA peripheral blood of sickle cell patients
- FIG. 5 Converting ⁇ S -globin transcripts into ⁇ -globin encoding RNAs.
- Trans-spliced products (5′S-3′g and ⁇ S -61-3′g) and free ribozyme (Rib61) are indicated.
- Molecular weight marker of 72 and 50 base pairs are shown.
- nucleic acid molecules such as, antisense, ribozyme or other nucleic acid-based molecules
- these oligonucleotides must be able to interact with their intended target nucleic acid (e.g., RNA) inside cells.
- RNA target nucleic acid
- cellular RNAs are not linear but rather adopt highly folded structures that make most of the nucleotides on the target RNA inaccessible to nucleic acid molecules, such as antisense and ribozyme molecules.
- the field has made a great number of different antisense or ribozyme molecules for a given target RNA and assessed the activity of the individual molecules in solution in a test tube (see for example McSwiggen et al., U.S. Pat. No. 5,525,468).
- Applicant has developed a novel approach to determine which regions of target RNAs are accessible by using a library of trans-splicing ribozymes.
- This approach takes advantage of the fact that such trans-splicing ribozymes covalently attach nucleotide Tag sequences onto their reaction sites.
- These attached Tag sequences serve as a convenient molecular tag that then allows one to subsequently identify the reaction site after simple reverse transcription (RT) and polymerase chain reaction (PCR) amplification (RT/PCR) and sequencing. Because this tagging can proceed in cells or in cell free systems using total RNA isolated from cells, it offers several significant advantages over the currently employed technology.
- this novel approach will greatly expedite the identification of accessible regions of target RNAs and therefore will be of great value in the development of useful nucleic acid-based therapeutic agents.
- RNA Tag can be made to contain the substrate recognition sequence for Q beta replicase which will be transferred to the target RNA during the reaction.
- part of the sequence required to generate the Q beta replicase substrate RNA can be made to be part of the substrate RNA upstream of the reaction site.
- the Q beta substrate RNA will only be generated by tagging of a specified reaction site with the appropriate RNA sequence. This strategy can be employed to make the reaction/amplification more specific when using RT/PCR amplification as well.
- RNA tagging can be made to proceed in cells as well as in the test tube. Therefore, tagging and even amplification (for example if Q beta replicase is coexpressed inside the cells) can be performed in a living cell providing a novel approach to nucleic acid amplification and diagnostics.
- the Tag can be a nucleic acid sequence (Tag sequence).
- the molecular tags and targets however do not necessarily have to be composed of nucleic acids.
- in vitro selection has allowed various groups to generate enzymatic nucleic acid molecules that can react with a range of non-nucleic acid molecules (Joyce, 1989, Gene, 82, 83-87; Beaudry et al., 1992, Science 257, 635-641; Joyce, 1992, Scientific American 267, 90-97; Breaker et al., 1994, TIBTECH 12, 268; Bartel et al., 1993, Science 261:1411-1418; Szostak, 1993, TIBS 17, 89-93; Kumar et al., 1995, FASEB J., 9, 1183; Breaker, 1996, Curr. Op.
- trans-splicing forms of these ribozymes should be able to covalently attach molecular tags to the non-nucleic acid reaction sites.
- ribozymes can be employed to specifically modify a variety of substrate molecules by covalently attaching molecular tags to their targets.
- the molecular Tags do not have to be composed of nucleic acid sequence.
- Similar selection should allow for the development of ribozymes that can covalently attach novel Tags to target molecules.
- ribozymes can be developed that can covalently modify a range of target molecules in a variety of ways. Such ribozymes can be used for a number of diagnostics and in manufacturing applications.
- ribozyme that will recognize the precursor of the final soap product, say a certain lipid, catalytically react with the lipid and covalently transfer a molecular group (the Tag in this case) to the target lipid to modify it in the desired manner.
- the ability of ribozymes to covalently attach molecules to specific substrate molecules allows us to employ ribozyme in ways that were not previously envisioned.
- the extra p53 gene was introduced into primary keratinocytes using a retroviral vector, and this p53 cDNA version of the gene was expressed from the Moloney murine leukemia virus LTR promoter.
- the cells transduced with the p53 gene were shown to express only a modest 2-4 fold increase in the wild type p53 protein as compared to cells transduced with control vectors. This modest additional p53 expression however resulted in extremely reduced growth rate, altered morphological differentiation and aberrant expression of genes normally associated with correct differentiation of keratinocytes.
- p53 suppressor genes are often mutated in transformed cells. Thus loss of tumor suppressor function appears to be a critical event during neoplastic transformation. In fact, about 60% of human cancers have mutations in the p53 tumor suppressor gene suggesting that p53 mutations may be the most common events in neoplastic transformation. A variety of mutations can apparently inactivate the p53 protein. Some cells have totally lost the p53 gene, however most express mutant p53 transcripts that contain missense point mutations between codons 120 and 290 of the 393 codon long gene.
- trans-splicing nucleic acid molecules can be used to repair the mutant p53 transcripts present in various tumor cells to restore the regulated expression of p53 and revert such cells from their transformed phenotypes.
- trans-splicing ribozymes are those that are known in the art (for e.g., group I or group II derived) or can be enzymatic nucleic acid molecules selected and/or evolved using selection techniques known in the art.
- these molecules can be supplemented by other molecules having a suitable splicing activity, or by spliceosomes or splicing factors.
- the various splicing factors and spliceosomes are well known in the art, and this activity is generally described by Bruziket al., 1992, Nature 360, 692, hereby incorporated by reference herein.
- the invention concerns splicing of target nucleic acid molecules and Tag sequence which are not normally spliced together within a cell as described by Bruzik et al., supra. Rather, as described above, a Tag sequence is selected such that a useful function can be achieved in a gene therapeutic fashion.
- the reaction involves base pairing of the catalytic nucleic acid molecule with the targeted transcript, cleavage of the targeted transcript, and then ligation of the3′ exon (Tag sequence) with this targeted 5′ exon.
- the catalytic nucleic acid is removed in the reaction.
- the specificity of the reaction can be changed by alteration of the substrate binding site in the catalytic nucleic acid molecule by methods well known in the art.
- Catalytic activity of the ribozymes described in the instant invention can be optimized as known in the art. The details will not be repeated here, but include altering the length of the ribozyme binding arms, or chemically synthesizing ribozymes with modifications (base, sugar and/or phosphate) that prevent their degradation by serum ribonucleases and/or enhance their enzymatic activity (see e.g., Eckstein et al., International Publication No. WO 92/07065; Perrault et al., 1990 Nature 344, 565; Pieken et al., 1991 Science 253, 314; Usman and Cedergren, 1992 Trends in Biochem. Sci.
- Ribozymes are modified to enhance stability and/or enhance catalytic activity by modification with nuclease resistant groups, for example, 2′-amino, 2′-C-allyl, 2′-flouro, 2′-O-methyl, 2′-H, nucleotide base modifications (for a review see Usman and Cedergren, 1992 TIBS 17, 34; Usman et al., 1994 Nucleic Acids Symp. Ser. 31, 163; Burgin et al., 1996 Biochemistry 35, 14090).
- nuclease resistant groups for example, 2′-amino, 2′-C-allyl, 2′-flouro, 2′-O-methyl, 2′-H, nucleotide base modifications
- Nucleic acid catalysts having chemical modifications which maintain or enhance enzymatic activity are provided. Such nucleic acid is also generally more resistant to nucleases than unmodified nucleic acid. Thus, in a cell and/or in vivo the activity may not be significantly lowered. As exemplified herein such ribozymes are useful in a cell and/or in vivo even if activity over all is reduced 10 fold (Burgin et al., 1996, Biochemistry, 35, 14090). Such ribozymes herein are said to “maintain” the enzymatic activity on all RNA ribozyme.
- Therapeutic ribozymes delivered exogenously must optimally be stable within cells until translation of the target RNA has been inhibited long enough to reduce the levels of the undesirable protein. This period of time varies between hours to days depending upon the disease state.
- ribozymes must be resistant to nucleases in order to function as effective intracellular therapeutic agents. Improvements in the chemical synthesis of RNA (Wincott et al., 1995 Nucleic Acids Res. 23, 2677; incorporated by reference herein) have expanded the ability to modify ribozymes by introducing nucleotide modifications to enhance their nuclease stability as described above.
- a “nucleotide” as used herein is as recognized in the art to include natural bases (standard), and modified bases well known in the art. Such bases are generally located at the 1′ position of a sugar moiety.
- Nucleotide generally comprise a base, sugar and a phosphate group.
- the nucleotides can be unmodified or modified at the sugar, phosphate and/or base moiety, (also referred to interchangeably as nucleotide analogs, modified nucleotides, non-natural nucleotides, non-standard nucleotides and other; see for example, Usman and McSwiggen, supra; Eckstein et al., International PCT Publication No.
- base modifications that can be introduced into enzymatic nucleic acids without significantly effecting their catalytic activity include, inosine, purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2,4,6-trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidines (e.g., 5-methylcytidine), 5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g.
- modified bases in this aspect is meant nucleotide bases other than adenine, guanine, cytosine and uracil at 1′ position or their equivalents; such bases may be used within the catalytic core of the enzyme and/or in the substrate-binding regions.
- unmodified nucleoside is meant one of the bases adenine, cytosine, guanine, uracil joined to the 1′ carbon of b-D-ribo-furanose.
- modified nucleoside is meant any nucleotide base which contains a modification in the chemical structure of an unmodified nucleotide base, sugar and/or phosphate.
- ribozyme structure can be made to enhance the utility of ribozymes. Such modifications will enhance shelf-life, half-life in vitro, stability, and ease of introduction of such ribozymes to the target site, e.g., to enhance penetration of cellular membranes, and confer the ability to recognize and bind to targeted cells.
- Sullivan et al. PCT WO 94/02595
- ribozymes may be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres.
- ribozymes may be directly delivered ex vivo to cells or tissues with or without the aforementioned vehicles.
- RNA/vehicle combination is locally delivered by direct injection or by use of a catheter, infusion pump or stent.
- routes of delivery include, but are not limited to, intravascular, intramuscular, subcutaneous or joint injection, aerosol inhalation, oral (tablet or pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal delivery. More detailed descriptions of ribozyme delivery and administration are provided in Sullivan et al., supra and Draper et al., PCT WO93/23569 which have been incorporated by reference herein.
- the molecules of the instant invention can be used as pharmaceutical agents.
- Pharmaceutical agents prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state in a patient.
- the negatively charged polynucleotides of the invention can be administered (e.g., RNA, DNA or protein) and introduced into a patient by any standard means, with or without stabilizers, buffers, and the like, to form a pharmaceutical composition.
- RNA, DNA or protein e.g., RNA, DNA or protein
- standard protocols for formation of liposomes can be followed.
- the compositions of the present invention may also be formulated and used as tablets, capsules or elixirs for oral administration; suppositories for rectal administration; sterile solutions; suspensions for injectable administration; and the like.
- the present invention also includes pharmaceutically acceptable formulations of the compounds described.
- formulations include salts of the above compounds, e.g., acid addition salts, for example, salts of hydrochloric, hydrobromic, acetic acid, and benzene sulfonic acid.
- a pharmacological composition or formulation refers to a composition or formulation in a form suitable for administration, e.g., systemic administration, into a cell or patient, preferably a human. Suitable forms, in part, depend upon the use or the route of entry, for example oral, transdermal, or by injection. Such forms should not prevent the composition or formulation to reach a target cell (i.e., a cell to which the negatively charged polymer is desired to be delivered to). For example, pharmacological compositions injected into the blood stream should be soluble. Other factors are known in the art, and include considerations such as toxicity and forms which prevent the composition or formulation from exerting its effect.
- systemic administration in vivo systemic absorption or accumulation of drugs in the blood stream followed by distribution throughout the entire body.
- Administration routes which lead to systemic absorption include, without limitations: intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary and intramuscular.
- Each of these administration routes expose the desired negatively charged polymers, e.g., nucleic acids, to an accessible diseased tissue.
- the rate of entry of a drug into the circulation has been shown to be a function of molecular weight or size.
- the use of a liposome or other drug carrier comprising the compounds of the instant invention can localize the drug, for example, in certain tissue types, such as the tissues of the reticular endothelial system (RES).
- RES reticular endothelial system
- a liposome formulation which can facilitate the association of drug with the surface of cells, such as, lymphocytes and macrophages is also useful. This approach may provide enhanced delivery of the drug to target cells by taking advantage of the specificity of macrophage and lymphocyte immune recognition of abnormal cells, such as the cancer cells.
- the invention also features the use of the a composition comprising surface-modified liposomes containing poly (ethylene glycol) lipids (PEG-modified, or long-circulating liposomes or stealth liposomes).
- PEG-modified, or long-circulating liposomes or stealth liposomes offer an method for increasing the accumulation of drugs in target tissues.
- This class of drug carriers resists opsonization and elimination by the mononuclear phagocytic system (MPS or RES), thereby enabling longer blood circulation times and enhanced tissue exposure for the encapsulated drug (Lasic et al. Chem. Rev. 1995, 95, 2601-2627; Ishiwataet al., Chem. Pharm. Bull. 1995, 43, 1005-1011).
- liposomes have been shown to accumulate selectively in tumors, presumably by extravasation and capture in the neovascularized target tissues (Lasic et al., Science 1995, 267, 1275-1276; Oku et al., 1995, Biochim. Biophys. Acta, 1238, 86-90).
- the long-circulating liposomes enhance the pharmacokinetics and pharmacodynamics of DNA and RNA, particularly compared to conventional cationic liposomes which are known to accumulate in tissues of the MPS (Liu et al., J. Biol. Chem. 1995, 42, 24864-24870; Choi et al., International PCT Publication No.
- WO 96/10391 Ansell et al., International PCT Publication No. WO 96/10390; Holland et al., International PCT Publication No. WO 96/10392; all of these are incorporated by reference herein).
- Long-circulating liposomes are also likely to protect drugs from nuclease degradation to a greater extent compared to cationic liposomes, based on their ability to avoid accumulation in metabolically aggressive MPS tissues such as the liver and spleen. All of these references are incorporated by reference herein.
- compositions prepared for storage or administration which include a pharmaceutically effective amount of the desired compounds in a pharmaceutically acceptable carrier or diluent.
- Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences , Mack Publishing Co. (A. R. Gennaro edit. 1985) hereby incorporated by reference herein.
- preservatives, stabilizers, dyes and flavoring agents may be provided. Id. at 1449. These include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid.
- antioxidants and suspending agents may be used. Id.
- a pharmaceutically effective dose is that dose required to prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state.
- the pharmaceutically effective dose depends on the type of disease, the composition used, the route of administration, the type of mammal being treated, the physical characteristics of the specific mammal under consideration, concurrent medication, and other factors which those skilled in the medical arts will recognize. Generally, an amount between 0.1 mg/kg and 100 mg/kg body weight/day of active ingredients is administered dependent upon potency of the negatively charged polymer.
- the trans-splicing nucleic acid molecules of the instant invention can be expressed within cells from eukaryotic promoters (e.g., Izant and Weintraub, 1985 Science 229, 345; McGarry and Lindquist, 1986 Proc. Natl. Acad. Sci. USA 83, 399; Scanlon et al., 1991, Proc. Natl. Acad. Sci USA, 88, 10591-5; Kashani-Sabet et al., 1992 Antisense Res. Dev., 2, 3-15; Dropulic et al., 1992 J. Virol, 66, 1432-41; Weerasinghe et al., 1991 J.
- eukaryotic promoters e.g., Izant and Weintraub, 1985 Science 229, 345; McGarry and Lindquist, 1986 Proc. Natl. Acad. Sci. USA 83, 399; Scanlon et al., 1991, Pro
- nucleic acids can be augmented by their release from the primary transcript by a ribozyme (Draper et al., PCT WO 93/23569, and Sullivan et al., PCT WO 94/02595; Ohkawa et al., 1992 Nucleic Acids Symp. Ser., 27, 15-6; Taira et al., 1991, Nucleic Acids Res., 19, 5125-30; Ventura et al., 1993 Nucleic Acids Res., 21, 3249-55; Chowrira et al., 1994 J. Biol. Chem. 269, 25856; all of the references are hereby incorporated in their totality by reference herein).
- a ribozyme Draper et al., PCT WO 93/23569, and Sullivan et al., PCT 94/02595; Ohkawa et al., 1992 Nucleic Acids Symp. Ser., 27, 15-6; Tair
- Trans-splicing nucleic acid molecules that cleave target molecules are expressed from transcription units (see for example Couture et al., 1996, TIG., 12, 510) inserted into DNA or RNA vectors.
- the recombinant vectors are preferably DNA plasmids or viral vectors. Ribozyme expressing viral vectors could be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus.
- the recombinant vectors capable of expressing the ribozymes are delivered as described above, and persist in target cells.
- viral vectors may be used that provide for transient expression of ribozymes. Such vectors might be repeatedly administered as necessary.
- the ribozymes cleave the target MRNA.
- the active ribozyme contains an enzymatic center or core equivalent to those in the examples, and binding arms able to bind target nucleic acid molecules such that cleavage at the target site occurs. Other sequences may be present which do not interfere with such cleavage. Delivery of ribozyme expressing vectors could be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from the patient followed by reintroduction into the patient, or by any other means that would allow for introduction into the desired target cell (for a review see Couture et al., 1996, TIG., 12,510).
- An expression vector comprising nucleic acid sequence encoding at least one of the trans-splicing nucleic acid molecules, such as a ribozyme, of the instant invention is disclosed.
- the nucleic acid sequence encoding the nucleic acid catalyst of the instant invention is operable linked in a manner which allows expression of that nucleic acid molecule.
- an expression vector compriseing: a transcription initiation region (e.g., eukaryotic pol I, II or III initiation region); b) a transcription termination region (e.g., eukaryotic pol I, II or III termination region); c) a gene encoding at least one of the nucleic acid catalyst of the instant invention; and wherein said gene is operably linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.
- the vector may optionally include an open reading frame (ORF) for a protein operably linked on the 5′ side or the 3′-side of the gene encoding the nucleic acid catalyst of the invention; and/or an intron (intervening sequences).
- ORF open reading frame
- RNA polymerase I RNA polymerase I
- RNA polymerase II RNA polymerase II
- RNA polymerase III RNA polymerase III
- Transcripts from pol II or pol III promoters will be expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type will depend on the nature of the gene regulatory sequences (enhancers, silencers, etc.) present nearby.
- Prokaryotic RNA polymerase promoters are also used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells (Elroy-Stein and Moss, 1990 Proc. Natl. Acad. Sci.
- transcription units such as the ones derived from genes encoding U6 small nuclear (snRNA), transfer RNA (tRNA) and adenovirus VA RNA are useful in generating high concentrations of desired RNA molecules such as ribozymes in cells (Thompson et al., supra; Couture and Stinchcomb, 1996, supra; Noonberg et al., 1994, Nucleic Acid Res., 22, 2830; Noonberg et al., U.S. Pat. No. 5,624,803; Good et al., 1997, Gene Ther. 4, 45; Beigelman et al., International PCT Publication No. WO 96/18736; all of these publications are incorporated by reference herein.
- ribozyme transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated virus vectors), or viral RNA vectors (such as retroviral or alphavirus vectors) (for a review see Couture and Stinchcomb, 1996, supra).
- plasmid DNA vectors such as adenovirus or adeno-associated virus vectors
- viral RNA vectors such as retroviral or alphavirus vectors
- Applicant also discloses an expression vector comprising nucleic acid sequence encoding at least one of the nucleic acid molecule of the invention, in a manner which allows expression of that nucleic acid molecule.
- the expression vector comprises in one embodiment; a) a transcription initiation region; b) a transcription termination region; c) a gene encoding at least one said nucleic acid molecule; and wherein said gene is operably linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.
- the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an open reading frame; d) a gene encoding at least one said nucleic acid molecule, wherein said gene is operably linked to the 3′-end of said open reading frame; and wherein said gene is operably linked to said initiation region, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.
- the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) a gene encoding at least one said nucleic acid molecule; and wherein said gene is operably linked to said initiation region, said intron and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.
- the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) an open reading frame; e) a gene encoding at least one said nucleic acid molecule, wherein said gene is operably linked to the 3′-end of said open reading frame; and wherein said gene is operably linked to said initiation region, said intron, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.
- RBC precursors (1 ⁇ 10 6 ) were resuspended in Opti-MEM (200 ml, Gibco-BRL), and ribozymes (2.5-5 mg) were lipofected into these cells using DMRIE-C (20 ml, Gibco-BRL) in Iml Opti-MEM for four hours. Then, DMEM (Gibco-BRL) with 10% fetal calf serum (1 ml) and erythropoeitin (2 u/ml) were added to the cells. Total RNA was isolated using TRI Reagent (Molecular Research Center) 16-24 hours after transfection. Transfection of these cells with a reporter RNA demonstrated that 1-2% of the erythrocyte precursors take up RNA.
- mapping library was generated by PCR amplification of the plasmid pT7L-21 with a 5′ primer containing a randomized sequence at the positions corresponding to the ribozyme's IGS (5′-GGGGGGATCCTAATACGACTCACTATAGNNNNNAAAAGTTATCA
- Ribozyme-3′ exon 100-500 ⁇ M
- substrate RNAs (1-5 mM or 1 ⁇ g cellular RNA) were denatured at 95° C. for 1 min in reaction buffer (50 mM HEPES pH7.0, 150 mM NaCl and 5 mM MgCl 2 ) and then equilibrated at 37° C. for 3 min.
- the substrates were then added to the ribozymes along with guanosine (100 mM) to start the reactions, which proceeded at 37° C. for 3 hours.
- reaction products were analyzed on a 4% polyacrylamide gel containing urea (8M).
- RT-PCR analysis Trans-splicing products were reverse-transcribed at 37° C. for 20 minutes in the presence of L-argininamide (10 mM) from a primer specific for the 3′ exon sequence as previously described.
- the resulting cDNAs were amplified for 30 cycles (in vitro ribozyme reactions) or 30-90 cycles (in vivo ribozyme reactions) using a 3′ exon primer (3′ tag primer: 5′-ATGCCTGCAGGTCGACTC, 3′gamma-globin primer: 5′-CCGGAATTCCCTTGTCCTCCTCTGTGA) and a 5′ primer specific for the beta-globin mRNA (5′GGGGATCCCTGTGTTCACTAGCAACC).
- the amplified products were separated on a 3% agarose gel and visualized by ethidium bromide staining.
- RNA mapping strategy that employs a trans-splicing ribozyme library and RNA tagging.
- the guide sequence of the Tetrahymena group I trans-splicing ribozyme was randomized such that the 5′ end of the RNAs in the library begin with 5′-GNNNNN-3′ where “G” represents guanine and “N” represents equal amounts of the 4 nucleotides 15 (FIG. 3 a ).
- the mapping library was incubated with total RNA isolated from erythrocyte precursors under splicing conditions.
- the trans-splicing reaction products were reverse transcribed (RT) and amplified by the polymerase chain reaction (PCR) using primers specific for the ribozyme's 3′ exon tag 6 and for the beta-globin target RNA (FIG. 3 a ).
- the resulting cDNAs were then sequenced to determine which uridine residues were present at the ribozyme reaction sites. From such analysis, the uridine at position 61 of beta-globin RNA appears particularly accessible because 5 out of 9 sequenced clones contain splice junctions at this nucleotide (FIG. 3 b ).
- mapping library was transfected into erythrocyte precursors. Total RNA was isolated from these cells and reactive uridines identified by RT-PCR amplification and sequence analysis. The uridine at position 61 also appears to be particularly accessible in vivo because in 5 of the 9 clones examined the 3′ exon tag had been spliced onto this nucleotide (FIG. 3 b ).
- Rib61 a ribozyme specific for site 61 .
- Rib61d an inactive version of this ribozyme, called Rib61d, which lacks part of the catalytic core of the enzyme was generated to control for the importance of ribozyme activity in these studies.
- Rib61 can trans-splice a3′ exon tag onto beta-globin transcripts in vitro and in erythrocyte precursors (FIG. 4).
- RT-PCR analyses were performed using one primer specific for the beta-globin target RNA and the other primer specific for the3′ exon tag sequence (FIG. 4 a ).
- Sickle cell anemia is the most common heritable hematological disease yet no curative treatment exists for this disorder. Moreover the intricacies of globin gene expression have made the development of gene therapy based treatments for hemaglobinopathies difficult. Applicant describes an alternative genetic approach to sickle cell therapy.
- a trans-splicing group I ribozyme can be employed to amend mutant beta-globin transcripts in erythroid lineage cells. To determine which regions of the beta-globin transcript are accessible to ribozymes inside cells, a novel RNA mapping strategy was developed that employs a trans-splicing ribozyme library and RNA tagging From such analysis, the uridine at position 61 of beta-globin RNA appears particularly accessible.
- trans-splicing ribozyme that recognizes this nucleotide reacts with beta-globin transcripts with high fidelity in erythrocyte precursors derived from normal umbilical cord blood or peripheral blood from individuals with sickle cell disease. Moreover such splicing can convert sickle beta -globin transcripts into RNAs encoding the anti-sickling protein gamma-globin.
- trans-splicing could be employed to repair mutant transcripts associated with a common genetic disorder
- the ribozyme recognizes the sickle beta-globin transcript by base pairing to an accessible region of the RNA upstream of the mutant nucleotide via an internal guide sequence (IGS), cleaves the ⁇ S -globin RNA, releases the mutation containing cleavage product and splices on the revised sequence for the globin transcript (FIG. 2A).
- IGS internal guide sequence
- erythrocyte precursors from normal umbilical cord blood (UCB) and from peripheral blood from patients with sickle cell disease by culturing the blood cells in serum free conditions supplemented with erythropoietin, Flt-3 ligand and IL-3.
- Nucleated red blood cells (RBC) appear by day 7 under these culture conditions and by three weeks they constitute 70-90% of the total number of cells in the culture as evidenced by Wright-Giemsa and immunofluorescent staining (FIG. 2).
- RBC red blood cells
- FIG. 2 because the majority of these erythroid lineage cells are late RBC precursors (FIG. 2), they are rich in globin transcripts making them ideal for the RNA repair studies described herein.
- RNA samples isolated from UCB and sickle cell patients were transfected into erythrocyte precursors derived from UCB and sickle cell patients.
- Total RNA was isolated from these cells and analyzed via RT-PCR to determine if trans-splicing products were present in any of the cellular samples (FIG. 4 b ).
- An amplified fragment of the expected size was generated from the RNA samples isolated from sickle cell patient and UCB derived RBC precursors that had been transfected with the active ribozyme. By contrast no such product was generated from RNA samples isolated from cells that were not transfected or were transfected with the inactive ribozyme.
- Rib61-3′Tag was added to the RNA extraction buffer used to isolate total RNA from a sample of mock transfected erythrocyte precursors. No amplification product was generated when this “mixed” RNA sample was analyzed by RT-PCR (FIG. 4 b ) suggesting that the observed trans-splicing products were generated inside the RBC precursors and not during RNA analysis.
- Trans-splicing nucleic acid molecules can be employed to correct a broad array of mutant transcripts associated with a variety of genetic disorders.
- a ribozyme can amend a disease related transcript, mutant ⁇ -globin mRNA, in clinically relevant cells, erythrocyte precursors derived from sickle cell patients.
- RNA repair may be a particularly appropriate genetic approach with which to treat sickle cell disease because the process should restore the regulated expression of anti-sickling versions of ⁇ -globin and simultaneously reduce the production of ⁇ S -globin (FIG. 2).
- the efficiency of ⁇ -globin RNA repair will likely not have to be 100% to benefit patients.
- Sickle cell trait is a benign condition that is not associated with increased morbidity or mortality and sickle cell patients that express ⁇ -globin at 10-20% the level of ⁇ S -globin in the majority of their RBCs have greatly improved clinical prognoses.
- the results presented here suggest that ribozyme-mediated repair of mutant RNAs may prove to be a useful approach to treat sickle cell disease and other inherited disorders.
- trans-splicing reaction to repair mutant beta-globin transcript can be tested in vivo using a variety of sickle cell disease animal models, prior to testing in humans (for e.g., see Ryan et al., 1997, Science 278, 873; Paszty et al., 1997, Science. 278,876; both are incorporated by reference herein).
- Radiolabeled Rib61-3′ ⁇ was allowed to react with an excess of unlabeled full length ( ⁇ S -FL) or truncated ( ⁇ S -61) ⁇ S -globin substrate RNA (FIG. 5). In both reactions, Rib61-3′ ⁇ was quickly converted to free ribozyme (Rib) plus ligated globin exons ( ⁇ S -61-3′ ⁇ ) with an approximate half-time (t 1 ⁇ 2 ) of 60 minutes. Rib61-3′ ⁇ reacted even faster (t 1 ⁇ 2 ⁇ 25 minutes) with a short 13 nucleotide substrate (5′SA 5 ). The inactive version of the ribozyme (Rib61d-3′ ⁇ ) was unable to mediate this splicing reaction (data not shown).
- Gene mapping and human genome sequencing provides the genetic basis for an increasing number of inherited diseases. With each discovery or identification of a new disease-related gene there is an opportunity to develop gene therapy based treatments.
- Trans-splicing nucleic acid molecules can be used to correct the defective transcripts issuing from mutant genes. This approach will be valuable for the treatment of the many genetic diseases caused by a common set of specific mutations which do not affect the expression of the mutant gene. For example, the genetic basis of many globin diseases is well understood. Targeted trans-splicing can repair or correct globin transcripts that are either truncated or contain point mutations. In the process, the cellular expression pattern of these genes is maintained. Therefore, targeted trans-splicing represents an important, novel strategy for the treatment of many genetic diseases.
- trans-splicing may also be accomplished without the use of ribozymes. It has been demonstrated that spliced leader sequences from lower eucaryotes can be trans-spliced onto mammalian3′ splice sites in tissue culture cells (Bruzik et al., Nature 360, 692 (1992)). Trans-splicing in this case is mediated by the spliceosome or splicing factors. There are several reports of protein dependent trans-splicing reactions in a variety of systems (see for example Ghetti et al., 1995, Proc. Natl. Acad. Sci., 92, 11461; Bruzik et al., supra). Thus, it is possible to employ spliceosomes to alter the sequence of targeted transcripts for some desired end via targeted trans-splicing.
- Trans-splicing nucleic acid molecules can be used to attach any Tag to a target nucleic acid molecules.
- the molecular Tags do not have to be composed of nucleic acid sequence.
- ribozymes can be developed that can covalently modify a range of target molecules in a variety of ways. Such ribozymes can be used for a number of diagnostics and in manufacturing applications.
- ribozyme that will recognize the precursor of the final soap product, say a certain lipid, catalytically react with the lipid and covalently transfer a molecular group (the Tag in this case) to the target lipid to modify it in the desired manner.
- the ability of ribozymes to covalently attach molecules to specific substrate molecules may allows us to employ ribozyme in ways that were not previously envisioned.
- Tags such as biotin can be attached to a target nucleic acid molecule (e.g., a pathogenic virus RNA)in vitro using trans-splicing ribozymes in biological sample from a patient.
- a target nucleic acid molecule e.g., a pathogenic virus RNA
- the extent of biotin attachment to the target RNA can be used as a measure of viral load in the patient; such measurements can be made using standard techniques such as using avidin to isolate biotin tagged RNA from the sample and quantifying the biotin tagged RNA.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
- This application claims priority to U.S. Provisional Application 60/067,834, Bruce A. Sullenger, et al., entitled “NUCLEIC ACID MEDIATED RNA TAGGING AND RNA REVISION”, filed Dec. 5, 1997, which is hereby incorporated herein by reference in its entirety, including any drawings and figures.
- [0002] This invention was made with Government support under Grant No(s) HL57606 awarded by the National Institutes of Health. The Government has certain rights in the invention.
- This invention relates to method and reagent for tagging nucleic acid molecules and repairing RNA molecules.
- The following is a brief description of RNA splicing and RNA processing reactions. This summary is not meant to be complete but is provided only for understanding of the invention that follows. This summary is not an admission that all of the work described below is prior art to the claimed invention.
- During gene expression, the information contained in a given protein encoding gene is directly copied into the corresponding pre-messenger RNA by transcription. The information embedded in this RNA is not fixed however and can be modified by splicing (Ruby et al., 1991TIGS 7,79; Guthrie, 1991, Science, 253, 157) or editing (Sollner-Webb, Curr. Opin. Cell Bio. 3, 1056) to remove, add or rewrite parts of the initial transcript. The self-splicing reaction of the group I intron ribozyme from Tetrahymena thermophila is perhaps the most thoroughly understood reaction that revises RNA. The intron performs two consecutive transesterification reactions to liberate itself and join flanking exon sequences (FIG. 1A) (Been et al., 1986, Cell, 47, 207). Careful analysis of this self-splicing reaction over the past decade has illustrated that the vast majority of sequence requirements for such excision are contained within the intron. No specific sequence requirements exist for the 3′ exon, and the only specific sequence requirement for 5′ exons is to have a uridine (U) preceding the cleavage site. In addition, base pairing must be maintained between the end of the 5′ exon and the 5′ exon-binding site present in the ribozyme so that the ribozyme can hold onto the 5′ exon after cleavage. These base pairs can be composed of any sets of complementary nucleotides however.
- Ribozyme mediated trans-splicing. In addition to performing self-splicing, the group I ribozyme from Tetrahymena can trans-splice an exon attached to its 3′ end onto a separate 5′ exon RNA (FIG. 1B). In this reaction, the 5′ exon is not covalently attached to the ribozyme but is bound via base pairing through the 5′ exon binding site on the ribozyme. In the process of pairing, a U is positioned across from the guanosine present at the 5′ end of the 5′ exon binding site. Once positioned, the ribozyme cleaves the bound substrate RNA at the reconstructed 5′ splice site and ligates its 3′ exon onto the 5′ exon cleavage product (FIG. 1B). Trans-splicing by group I ribozymes is extremely malleable. Virtually any U residue in a 5′ exon can be targeted for splicing by altering the nucleotide composition of the 5′ exon binding site on the ribozyme to make it complementary to a target sequence present on the substrate RNA. Because no specific 3′ exon sequences are required, virtually any 3′ exon sequence can be spliced onto a targeted U residue by such a reaction.
- Directed RNA revision by trans-splicing in bacteria. A trans-splicing ribozyme can be employed to revise the sequence of targeted RNAs. In the first example of this application, we recently demonstrated that a trans-splicing group I ribozyme from Tetrahymena can be employed to repair truncated lacZ transcripts (Sullenger et al., 1994,Nature 371, 619; Sullenger et al., U.S. Pat. No. 5,667,969; both are incorporated by reference herein). In this system, a 3′ exon sequence encoding the restorative lacZ sequence was attached to the splicing ribozyme. For trans-splicing to correct the defective lacZ messages, the ribozyme must recognize the truncated 5′ lacZ transcript by base pairing, cleave off additional nucleotides, hold onto the 5′ lacZ cleavage product, and ligate the
restorative lacZ 3′ exon sequence onto the cleaved 5′ product to yield the proper open reading frame for translation. It was shown that the ribozyme could faithfully accomplish such RNA revision both in vitro and in Escherchia coli. Furthermore, in E. coli the repaired RNAs went on to be translated to produce a functional enzyme. - Inoue et al., 1985,Cell 43, 431; state that short oligonucleotides of 2-6 nucleotides can undergo intermolecular exon ligation or splicing in trans. It indicates that “long 5′ exons should be reactive provided that three conditions are met: the exon must have a 3′ hydroxyl group, it must terminate in a sequence similar to that of the 3′ end of the 5′ exon, and the 3′ terminal sequence must be available as opposed to being tied up in some secondary structure. Thus, it appears that exon switching is possible in this system, though limited by the availability of alternative 5′ exons that meet the above criteria. These could include transcripts that are not 5′ exons from other precursors, since RNA polymerases always leave 3′ hydroxyl ends.”
- Haseloff et al., U.S. Pat. No. 5,641,673 describe a method of “cell ablation . . . that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing group I trans-splicing ribozyme.”
- Mitchell et al., International PCT Publication No. WO 97/22250, describe a method of trans-splicing to “selectively kill target cells.”
- This invention features a method in which a mutant beta-globin transcripts are altered by use of a splicing reaction in vivo or in vitro. It involves the manipulation of genetic information to ensure that a useful transcript is provided within a cellular system or extract. The invention also features a method of identifying regions in a target RNA that are accessible to interaction with separate macromolecules such as nucleic acid molecules, using trans-splicing nucleic acid molecules. The invention further describes a method of attaching non-nucleic acid Tags to target nucleic acid molecules.
- In a preferred embodiment, the trans-splicing nucleic acid molecules are enzymatic nucleic acid molecules. More specifically the trans-splicing nucleic acid molecules are derived from group I (Sullenger et al., supra) or group II introns (Jacquier, 1990,TIBS 15, 351; Michels et al., 1995, Biochemistry, 34, 2965; Chanfreau et al., 1994, Science, 266, 1383; Mueller et al., 1993, Science, 261, 1035; Jarrell et al., U.S. Pat. No. 5,498,531; all are incorporated herein by reference).
- In another preferred embodiment, the trans-splicing nucleic acid molecules facilitate trans-splicing reaction in the presence of one or more cellular factors, such as protein factors (Bruzik et al., supra; Jarrell supra; Ghetti et al., 1995,Proc. Natl. Acad. Sci., 92, 11461; all are incorporated by reference herein). Preferably, such trans-splicing nucleic acid molecules are derived from pre-messenger RNA introns, but can also be derived from other introns such as group I and group II.
- In a first aspect the invention features a method of replacing a region of a mutant beta-globin RNA molecule containing one or more mutations with a desired beta-globin sequence using trans-splicing nucleic acid molecules, to generate a beta-globin RNA molecule able to express a protein with normal beta-globin protein attributes (FIG. 2A). The method involves: a) contacting the target RNA molecule (e.g., mutant beta-globin RNA) in vitro or in vivo with a trans-splicing nucleic acid molecule (e.g. group I intron ribozyme, group II intron ribozyme, pre-mRNA intron or the like), comprising a Tag with a defined sequence (e.g., desired beta-globin sequence with out deleterious mutations); b) the trans-splicing nucleic acid molecule is incubated with the target RNA molecule under conditions suitable for trans-splicing reaction to occur; the trans-splicing reaction removes the defective (mutant) region of the beta-globin RNA and in its place covalently attaches the desired beta-globin sequence in the target RNA molecule.
- By “desired beta-globin” sequence is meant sequence of beta-globin RNA that does not have mutations that are deleterious to the normal function of a wild type beta-globin protein (see Andrin et al., 1994,Biochem. Cell. Bio. 72, 377; Orkin, 1990, Cell, 63, 665).
- By “normal beta-globin protein attributes” is meant function or properties of a beta-globin protein that are not associated with a disease or a condition (see Andrin et al., 1994,Biochem. Cell. Bio. 72, 377; Orkin, 1990, Cell, 63, 665).
- In a second preferred embodiment, the invention features a method of converting mutant beta-globin RNA molecule containing one or more mutations into a chimeric beta-gamma-globin sequence using trans-splicing nucleic acid molecules, to generate a RNA molecule able to express a protein with normal gamma-globin protein fuction and properties. The method involves: a) contacting the target RNA molecule (e.g., mutant beta-globin RNA) in vitro or in vivo with a trans-splicing nucleic acid molecule (e.g. group I intron ribozyme, group II intron ribozyme, pre-mRNA intron or the like), comprising a Tag with a defined sequence (e.g., a gamm-globin sequence); b) the trans-splicing nucleic acid molecule is incubated with the target RNA molecule under conditions suitable for trans-splicing reaction to occur; the trans-splicing reaction removes the defective (mutant) region of the beta-globin RNA and in its place covalently attaches the gamma-globin sequence in the target RNA molecule to generate a chimeric beta-gamma-globin RNA.
- By “chimeric beta-gamma-globin sequence” is meant a gamma-globin sequence having one or more regions of beta-globin RNA and where the chimeric sequence is able to express a protein having the function and one or more properties of a gamma globin protein (see Andrin et al., 1994,Biochem. Cell. Bio. 72, 377; Orkin, 1990, Cell, 63, 665).
- The trans-splicing nucleic acid molecule is not naturally associated with the Tag sequence since it is not generally desired to splice the Tag sequence of a naturally occurring nucleic acid molecule with a target RNA molecule. Rather, the Tag sequence is chosen or selected to have a desired function once spliced with the target nucleic acid molecule.
- In preferred embodiments, the catalytic nucleic acid molecule is able to cleave and splice, e.g., it has a group I (Sullenger et al., supra) or group II intron (Jacquier, 1990,TIBS 15, 351; Michels et al., 1995, Biochemistry, 34, 2965; Chanfreau et al., 1994, Science, 266, 1383; Mueller et al., 1993, Science, 261, 1035; Jarrell et al., U.S. Pat. No. 5,498,531; all are incorporated herein by reference) motif; the method is performed in vitro or in vivo with an RNA target; and the method can be used to treat genetic disease in a gene therapy type manner, for example, by correcting an abnormal transcript.
- In other aspects, the invention features catalytic nucleic acid molecules having a desired Tag sequence as a 3′ exon encoding at least a portion of a useful gene which can be used in gene therapy. The Tag sequence can also be attached to a target RNA (for example associated with a certain disease condition) in a biological sample, for example from a patient for diagnostic purposes; the Tag sequence is used as an indicator of the presence and quantity of the target RNA in a sample. Such a molecule can be spliced with and thereby correct or modify the expression of other target RNA molecules. The invention also features vectors encoding such catalytic nucleic acid molecules.
- In a third preferred embodiment, the invention features a method of identifying a region or regions in a target RNA molecule that is accessible to interaction (e.g., hybridization) with a separate nucleic acid molecule involving: a) contacting the target RNA molecule in vitro or in vivo with an enzymatic nucleic acid molecule with trans-splicing activity (e.g. group I intron ribozyme, group II intron ribozyme or the like), comprising a Tag with a defined sequence; b) the enzymatic nucleic acid molecule is incubated with the target RNA molecule under conditions suitable for trans-splicing reaction to occur; the trans-splicing reaction covalently attaches the Tag sequence to the target RNA molecule to form a chimeric RNA molecule; and c) identifying the accessible region in the target RNA; the region of target RNA molecule where the Tag sequence has been inserted (accessible region) is readily identified using standard molecular biology techniques such as reverse transcription and polymerase chain reaction.
- In a further embodiment, the invention features a method of identifying a region or regions in a target RNA molecule that is accessible to interaction (e.g., hybridization) with a separate nucleic acid molecule including the step of contacting the target RNA molecule in vitro or in vivo with an enzymatic nucleic acid molecule with trans-splicing activity (e.g. group I intron ribozyme, group II intron ribozyme or the like), comprising a Tag with a defined sequence. The enzymatic nucleic acid molecule includes a target binding domain and an enzymatic domain, where the target binding domain has a randomized region. The enzymatic nucleic acid molecule with randomized binding arm is contacted with target RNA molecule under conditions suitable for the attachment of the Tag sequence to the target RNA. The region of the target RNA with the inserted Tag sequence is identified readily using standard molecular biology techniques.
- By “randomized region” is meant a region of completely random sequence and/or partially random sequence. By completely random sequence is meant a sequence wherein theoretically there is equal representation of A, U, G and C nucleotides or modified derivatives thereof, at each position in the sequence. By partially random sequence is meant a sequence wherein there is an unequal representation of A, U, G and C nucleotides or modified derivatives thereof, at each position in the sequence. A partially random sequence can therefore have one or more positions of complete randomness and one or more positions with defined nucleotides.
- By “separate nucleic acid molecule” is meant a nucleic acid molecule capable of interacting with a target nucleic acid molecule and modulate the expression and/or function of the target nucleic acid molecule. Such separate nucleic acid molecules include enzymatic nucleic acid molecules, antisense oligonucleotides, triplex forming oligonucleotides, peptide nucleic acid molecules, aptamers, 2-5 A antisense chimeras, and others.
- By “antisense oligonucleotide” it is meant a non-enzymatic nucleic acid molecule that binds to target RNA by means of RNA-RNA or RNA-DNA or RNA-PNA (protein nucleic acid; Egholm et al., 1993Nature 365, 566) interactions and alters the activity of the target RNA (for a review see Stein and Cheng, 1993 Science 261, 1004; Agrawal et al., U.S. Pat. No. 5,591,721; Agrawal, U.S. Pat. No. 5,652,356).
- By “2-5 A antisense chimera” it is meant, an antisense oligonucleotide containing a 5′ phosphorylated 2′-5′-linked adenylate residues. These chimeras bind to target RNA in a sequence-specific manner and activate a cellular 2-5A-dependent ribonuclease which, in turn, cleaves the target RNA (Torrence et al., 1993Proc. Natl. Acad. Sci. USA 90, 1300).
- By “triplex forming oligonucleotides (TFO)” it is meant an oligonucleotide that can bind to a double-stranded DNA in a sequence-specific manner to form a triple-strand helix. Formation of such triple helix structure has been shown to inhibit transcription of the targeted gene (Duval-Valentin et al., 1992Proc. Natl. Acad. Sci. USA 89, 504).
- By “oligonucleotide” as used herein is meant a molecule having two or more nucleotides. The polynucleotide can be single, double or multiple stranded and may have modified or unmodified nucleotides or non-nucleotides or various mixtures and combinations thereof.
- By “nucleic acid molecule” as used herein is meant a molecule having nucleotides. The nucleic acid can be single, double or multiple stranded and may comprise modified or unmodified nucleotides or non-nucleotides or various mixtures and combinations thereof. An example of a nucleic acid molecule according to the invention is a gene which encodes for macromolecule such as a protein.
- By “complementarity” as used herein is meant a nucleic acid that can form hydrogen bond(s) with other nucleic acid sequence by either traditional Watson-Crick or other non-traditional types (for example, Hoogsteen type) of base-paired interactions.
- By “enzymatic nucleic acid” it is meant a nucleic acid molecule capable of catalyzing reactions including, but not limited to, site-specific cleavage and/or ligation of other nucleic acid molecules, cleavage of peptide and amide bonds, and trans-splicing (see for example (Zaug et al., 324,Nature 429 1986; Cech, 260 JAMA 3030, 1988; Usman & McSwiggen, 1995 Ann. Rep. Med. Chem. 30, 285-294; Christoffersen and Marr, 1995 J. Med. Chem. 38, 2023-2037; all are incorporated by reference herein). Such a molecule with endonuclease activity may have complementarity in a substrate binding region to a specified gene target, and also has an enzymatic activity that specifically cleaves RNA or DNA in that target. This complementarity functions to allow sufficient hybridization of the enzymatic RNA molecule to the target RNA or DNA to allow the cleavage to occur. 100% complementarity is preferred, but complementarity as low as 50-75% may also be useful in this invention. The nucleic acids may be modified at the base, sugar, and/or phosphate groups. The term enzymatic nucleic acid is used interchangeably with phrases such as ribozymes, catalytic RNA, enzymatic RNA, catalytic DNA, catalytic oligonucleotides, nucleozyme, DNAzyme, RNA enzyme, endoribonuclease, endonuclease, minizyme, leadzyme, oligozyme or DNA enzyme. All of these terminologies describe nucleic acid molecules with enzymatic activity. The specific enzymatic nucleic acid molecules described in the instant application are not limiting in the invention and those skilled in the art will recognize that all that is important in an enzymatic nucleic acid molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target nucleic acid regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart a nucleic acid cleaving/ligation activity to the molecule.
- By “enzymatic portion” or “catalytic domain” is meant that portion/region of the ribozyme necessary for catalytic activity (for example see FIG. 1).
- By “substrate binding arm” or “substrate binding domain” is meant that portion/region of a ribozyme which is complementary to (i e., able to base-pair with) a portion of its substrate. Generally, such complementarity is 100%, but can be less if desired. For example, as few as 10 bases out of 14 may be base-paired. Such arms are shown generally in FIG. 1 and2. That is, these arms contain sequences within a ribozyme which are intended to bring ribozyme and target RNA together through complementary base-pairing interactions. The ribozyme of the invention may have binding arms that are contiguous or non-contiguous and may be of varying lengths. The length of the binding arm(s) are preferably greater than or equal to four nucleotides; specifically 12-100 nucleotides; more specifically 14-24 nucleotides long. If two binding arms are chosen, the design is such that the length of the binding arms are symmetrical (i e., each of the binding arms is of the same length; e.g., five and five nucleotides, six and six nucleotides or seven and seven nucleotides long) or asymmetrical (i.e., the binding arms are of different length; e.g., six and three nucleotides; three and six nucleotides long; four and five nucleotides long; four and six nucleotides long; four and seven nucleotides long; and the like). Those of ordinary skill in the art will recognize that other motifs than those of the group I and group II introns may also be manipulated to provide useful trans-splicing activity.
- The conditions chosen for the contacting step and the trans-splicing step may be those naturally occurring within a cell, or may be manipulated in vitro to ensure that the splicing reaction will occur. These conditions are well known to those in the art, for example, as described by Inoue et al., supra.
- In a fourth embodiment the invention features a method of attaching a Tag moiety other than nucleic acid to a target nucleic acid using enzymatic trans-splicing nucleic acid molecules, comprising the step of contacting the target nucleic acid molecule with the enzymatic trans-splicing nucleic acid molecule comprising a Tag under conditions suitable for the attachment of the Tag.
- By “Tag sequence” is meant a non-naturally occuring sequence with a few nucleotides (10-500 nucleotides) or may be significantly greater and may represent almost all of a molecule encoding a gene product (i.e., at least 1 to 5 kbases).
- By “Tag” is meant a chemical moiety that can be linked to a target nucleic acid molecule using a trans-splicing nucleic acid molecule. Non-limiting examples of a Tag are nucleic acid, nucleotides, nucleoside triphosphate, lipid moiety, carbohydrate moiety, biotin, a detergent, peptide, aminoacid, antibiotic, and others. More specifically the Tag moiety is selected from a group consisiting of a lipid, carbohydrate, vitamin, biotin, a fluoroscence compound (e.g., fluorescein, rhodamine and the like), peptide (e.g., peptides to facilitate intracellular trafficking of nucleic acid molecules), aminoacid, antibody and an antibiotic.
- By “target nucleic acid molecule” is meant any nucleic acid molecule that serve as a target for interaction with a trans-splicing nucleic acid molecule.
- The “chimeric RNA molecule” is one which is a non-naturally occuring not present in the system prior to the initiation and completion of trans-splicing reaction. Alternatively, it may be a completely novel structure which does not occur in nature, but which is useful in gene therapeutic treatment of an organism.
- Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.
- The drawings will briefly be described.
- FIG. 1A is a diagrammatic representation showing splicing reactions of the group I intron from Tetrahymena. FIG. 1B, shows a schemmatic representation of a strategy for targeted trans-splicing.
- FIG. 2 shows a scheme for ribozyme-mediated repair of sickle beta-globin transcripts. A) Scheme for the conversion of βS-globin mRNAs into transcripts encoding desired β-globin. b) Scheme for the conversion of βS-globin mRNAs into transcripts encoding chimeric β-γ-globin. Xm, sickle beta-globin point mutation; γ-3′exon, restorative globin sequence.
- FIG. 3 shows a scheme for identifying accessible regions within beta-globin RNA using trans-splicing ribozyme. a) A library of trans-splicing ribozymes containing randomized guide sequences (5′-GNNNNN-3′) is incubated with beta-globin mRNA. Ribozymes in the library that react with accessible uridine residues on beta-globin transcripts attach their 3′ exon Tag to these sites. These “Tagged” reaction products are amplified by RT/PCR using a primer (D) specific to the 3′exon Tag and a primer (U) specific for the beta-globin RNA. These amplified fragments are cloned and sequenced to determine which uridines are present at the ribozyme reaction sites. b) Mapping results. Nucleotide positions are presented for the accessible uridines identified from in vitro (left) and in vivo (right) mapping analysis. The number of individual clones containing a given uridine at the splice site is indicated.
Position 70 denotes the nucleotide that is altered in sickle beta-globin transcripts. - FIG. 4. Trans-splicing a3′ exon Tag onto beta-globin transcripts. a) RT-PCR analysis of trans-spliced RNA products generated in vitro. Active (Rib61-3′tag) and inactive (Rib61d-3′tag) ribozymes were incubated with a truncated βS-globin transcript (βS-61) that contains the first 61 nucleotides of the RNA, the full length βS-globin transcript (βS-FL) or total RNA isolated from erythrocyte precursors derived from normal umbilical cord blood (UCB RNA) or from peripheral blood of sickle cell patients (SC RNA). Amplification of trans-splicing reaction products is expected to yield a 93 base pair product. A 50 base pair DNA ladder provided molecular mass markers. b) RT-PCR analysis of trans-spliced RNA products generated in RBC precursors. Erythrocyte precursors derived from normal umbilical cord blood (UCB) or peripheral blood of sickle cell patients (SC) were mock transfected (mock and mix) or transfected with the active (Rib61-3′tag) or inactive (Rib61d-3′tag) ribozymes. RNA was harvested from these cells and trans-spliced products analyzed as in FIG. 4a. In the “mix” sample, Rib61-3′tag was added to the RNA extraction buffer prior to RNA isolation.
- FIG. 5. Converting βS-globin transcripts into γ-globin encoding RNAs. a) In vitro trans-splicing reaction. Body-labeled ribozyme-3′γ globin RNA (Rib61-3′γ) was incubated under splicing conditions with full length βS-globin RNA (βS-FL), truncated βS-globin RNA (βS-61A3:61 nucleotides of βS-globin RNA plus 3 adenosine residues) and a 13 nucleotide substrate (5′SA5:GGGCACCUAAA) for the indicated times. Trans-spliced products (5′S-3′g and βS-61-3′g) and free ribozyme (Rib61) are indicated. b) RT-PCR analysis of amended RNAs generated in erythrocyte precursors from normal umbilical cord blood (UCB) or peripheral blood of sickle cell patients (SC). Cells were mock transfected (mock and mix) or transfected with the active (Rib61-3′γ) or inactive (Rib61d-3′γ) ribozymes. Amended RNAs were amplified by RT/PCR and yield a DNA fragment of 62 base pairs. In the mix samples, Rib61-3′γ was added to the RNA extraction buffer before RNA isolation. Molecular weight marker of 72 and 50 base pairs are shown. c) Sequence of amended βS-globin transcripts. The expected sequence for a corrected transcript around the splicing junction is shown, with the complement to the IGS shaded and the uridine at
position 61 circled. βS-globin and γ-globin sequences are provided for comparison and the mutant nucleotide in the sickle β-globin transcript indicated. Translation of the amended transcript would yield γ-globin with three amino acids derived from β-globin. - To successfullly employ separate nucleic acid molecules such as, antisense, ribozyme or other nucleic acid-based molecules, to modulate gene expression, these oligonucleotides must be able to interact with their intended target nucleic acid (e.g., RNA) inside cells. Unfortunately, cellular RNAs are not linear but rather adopt highly folded structures that make most of the nucleotides on the target RNA inaccessible to nucleic acid molecules, such as antisense and ribozyme molecules. Thus, it has become useful in the field of nucleic acid therapeutics to determine which regions of folded target RNAs are accessible to interactions (e.g., base pairing) with these separate nucleic acid molecules. To identify such accessible regions, the field has made a great number of different antisense or ribozyme molecules for a given target RNA and assessed the activity of the individual molecules in solution in a test tube (see for example McSwiggen et al., U.S. Pat. No. 5,525,468).
- Applicant has developed a novel approach to determine which regions of target RNAs are accessible by using a library of trans-splicing ribozymes. This approach takes advantage of the fact that such trans-splicing ribozymes covalently attach nucleotide Tag sequences onto their reaction sites. These attached Tag sequences serve as a convenient molecular tag that then allows one to subsequently identify the reaction site after simple reverse transcription (RT) and polymerase chain reaction (PCR) amplification (RT/PCR) and sequencing. Because this tagging can proceed in cells or in cell free systems using total RNA isolated from cells, it offers several significant advantages over the currently employed technology. First, it allows one to simultaneously map a number of target transcripts by simply employing different amplification primers which greatly increases mapping through put. Second, it allows one to map the actual target RNA of interest inside cells by transfecting the library of trans-splicing ribozymes directly into cells. Thus, this novel approach will greatly expedite the identification of accessible regions of target RNAs and therefore will be of great value in the development of useful nucleic acid-based therapeutic agents.
- It should be noted that other approaches for amplification of reaction products exist including amplification of chimeric RNAs by Q beta replicase. The RNA Tag can be made to contain the substrate recognition sequence for Q beta replicase which will be transferred to the target RNA during the reaction. To generate more reaction/amplification specificity, part of the sequence required to generate the Q beta replicase substrate RNA can be made to be part of the substrate RNA upstream of the reaction site. Thus the Q beta substrate RNA will only be generated by tagging of a specified reaction site with the appropriate RNA sequence. This strategy can be employed to make the reaction/amplification more specific when using RT/PCR amplification as well.
- It should be noted that RNA tagging can be made to proceed in cells as well as in the test tube. Therefore, tagging and even amplification (for example if Q beta replicase is coexpressed inside the cells) can be performed in a living cell providing a novel approach to nucleic acid amplification and diagnostics.
- Attachment of Molecular Tag:
- As previously described Applicant provides a means of attaching molecular tags to targeted nucleic acids using trans-splicing reaction. The Tag can be a nucleic acid sequence (Tag sequence). The molecular tags and targets however do not necessarily have to be composed of nucleic acids. For example, in vitro selection has allowed various groups to generate enzymatic nucleic acid molecules that can react with a range of non-nucleic acid molecules (Joyce, 1989,Gene, 82, 83-87; Beaudry et al., 1992, Science 257, 635-641; Joyce, 1992, Scientific American 267, 90-97; Breaker et al., 1994, TIBTECH 12, 268; Bartel et al., 1993, Science 261:1411-1418; Szostak, 1993, TIBS 17, 89-93; Kumar et al., 1995, FASEB J., 9, 1183; Breaker, 1996, Curr. Op. Biotech., 7, 442; Santoro et al., 1997, Proc. Natl. Acad. Sci., 94, 4262; Tang et al., 1997,
RNA 3, 914; Robertson et al., 1997, Curr. Bio. 7, R376; Jhaveri et al., 1997, Ann. Rep. Comb. Chem. Mol Diversity, 1, 169; all are incorporated by reference herein). Thus trans-splicing forms of these ribozymes should be able to covalently attach molecular tags to the non-nucleic acid reaction sites. Thus ribozymes can be employed to specifically modify a variety of substrate molecules by covalently attaching molecular tags to their targets. - Similarly, the molecular Tags do not have to be composed of nucleic acid sequence. One can simply alter the molecular composition of the 3′ exon Tag attached to the ribozyme. Just as in vitro selection has allowed for the generation of novel ribozymes with new cleavage activities, similar selection should allow for the development of ribozymes that can covalently attach novel Tags to target molecules. Thus ribozymes can be developed that can covalently modify a range of target molecules in a variety of ways. Such ribozymes can be used for a number of diagnostics and in manufacturing applications. For example, if one wants to a make a soap that has a specific type of chemical linkage that is difficult to generate by classical organic chemistry techniques, now one can consider the generation of a ribozyme that will recognize the precursor of the final soap product, say a certain lipid, catalytically react with the lipid and covalently transfer a molecular group (the Tag in this case) to the target lipid to modify it in the desired manner. Thus, the ability of ribozymes to covalently attach molecules to specific substrate molecules allows us to employ ribozyme in ways that were not previously envisioned.
- Conventional gene therapy. In this era of molecular medicine, the genetic basis for an increasing number of inherited diseases including many types of cancer is being discovered. Gene therapy represents a new and exciting approach for the treatment of such diseases (Morgan, 1993,Ann. Rev. Biochem., 62:191-217). In its conception, gene therapy seemed quite simple. To treat a genetic deficiency give a functional copy of the defective gene to the cells of the deficient patient. To accomplish this in practice, most often a viral vector is used to transfer a cDNA copy of the wild type gene, which is usually under the control of a heterologous promoter, to cells harboring a mutant version. If the human genome were a simple warehouse of information, this approach would be quite successful. Unfortunately for the gene therapist, our genome appears to be extremely complicated, and expression of the information contained within it is apparently highly regulated. This complexity may severely limit the utility of the simple gene “add back” approach to gene therapy. Regrettably, cDNA versions of genes that are integrated in incorrect locations in the genome and that are expressed from heterologous promoters will almost assuredly not recapitulate the normal expression pattern of their endogenous counterparts. Therefore, significant technical advances may be necessary if the simple gene add back approach is to become useful for the treatment of genetic disorders associated with genes which require regulated expression to function properly.
- Because genes associated with tumorigenesis normally control cell growth and differentiation, their expression will most likely have to be tightly regulated to coordinate cell cycle progression and development. At least three observations support this theory. First, deregulated expression of the transcription factor E2F-1 engenders premature entry into S-phase and can lead to p53 dependent apoptosis suggesting that expression of cell cycle proteins must be properly regulated for normal cell replication to proceed (Wu et al., 1994Proc. Natl. Acad. Sci. USA, 91:3602-3606; Qin et al., 1994 Proc. Natl. Acad. Sci. USA, 91:10918-10922; Shan et al., 1994 Mol. Cell. Biol., 14:8166-8173; Kowalik et al., 1995, J Virol 69:2491-2500). Furthermore, as pointed out in a recent review by Weinberg (Cancer Surveys 1992;12:43-57), it has been difficult to restore normal growth to tumor cells harboring a mutant Rb (retinoblastoma) gene by retroviral vector mediated-transfer of a wild type cDNA copy of Rb to such cells. Although some groups have reported success with such experiments other have found that introduction of the Rb gene profoundly inhibited cell growth making it difficult to generate enough cells to perform experiments. Such results led Weinberg to state: “Perhaps a well regulated cloned Rb gene rather than one driven by a strong constitutive transcriptional promoter will yield cells that have lost tumorigenisity without loss of in vitro growth potential” (supra). If such regulated expression is required to correctly revert tumorigenisity in vitro, it will almost certainly be useful for reversion in vivo. Finally, it has been demonstrated that overexpression of the wild type p53 gene aberrantly alters growth and differentiation of normal human keratinocytes eventhough these cells normally express some natural level of the p53 protein from their wild type, endogenous genes (Woodworth et al., Cell Growth & Differ 1993;4:367-376). In these experiments, the extra p53 gene was introduced into primary keratinocytes using a retroviral vector, and this p53 cDNA version of the gene was expressed from the Moloney murine leukemia virus LTR promoter. The cells transduced with the p53 gene were shown to express only a modest 2-4 fold increase in the wild type p53 protein as compared to cells transduced with control vectors. This modest additional p53 expression however resulted in extremely reduced growth rate, altered morphological differentiation and aberrant expression of genes normally associated with correct differentiation of keratinocytes. Thus coordinated expression of the p53 gene is apparently important for proper growth, development and differentiation of primary human cells and incorrect expression can lead to dramatic phenotypic aberrations.Tumor suppressor genes are often mutated in transformed cells. Thus loss of tumor suppressor function appears to be a critical event during neoplastic transformation. In fact, about 60% of human cancers have mutations in the p53 tumor suppressor gene suggesting that p53 mutations may be the most common events in neoplastic transformation. A variety of mutations can apparently inactivate the p53 protein. Some cells have totally lost the p53 gene, however most express mutant p53 transcripts that contain missense point mutations between codons 120 and 290 of the 393 codon long gene. In breast cancers, the p53 gene is mutated approximately 40% of the time with most mutations found in exons 5-8 of the gene. Therefore, trans-splicing nucleic acid molecules can be used to repair the mutant p53 transcripts present in various tumor cells to restore the regulated expression of p53 and revert such cells from their transformed phenotypes.
- Trans-Splicinz Ribozymes:
- The general scheme for a targeted trans-splicing is shown in FIG. 1. Those in the art will recognize that any enzymatic nucleic acid molecule having the appropriate splicing activity can be used in the invention. The trans-splicing ribozymes are those that are known in the art (for e.g., group I or group II derived) or can be enzymatic nucleic acid molecules selected and/or evolved using selection techniques known in the art. There are several reports on in vitro selection protocols; following are examples of publications relating to the in vitro selection techniques all of which are incorporated herein by reference-Joyce, 1989,Gene, 82, 83-87; Beaudry et al., 1992, Science 257, 635-641; Joyce, 1992, Scientific American 267, 90-97; Breaker et al., 1994, TIBTECH 12, 268; Bartel et al., 1993, Science 261:1411-1418; Szostak, 1993, TIBS 17, 89-93; Kumar et al., 1995, FASEB J., 9, 1183; Breaker, 1996, Curr. Op. Biotech., 7, 442; Santoro et al., 1997, Proc. Natl. Acad. Sci., 94, 4262; Tang et al., 1997,
RNA 3, 914; Robertson et al., 1997, Curr. Bio. 7, R376; Jhaveri et al., 1997, Ann. Rep. Comb. Chem. Mol Diversity, 1, 169). - Alternatively, as discussed above, these molecules can be supplemented by other molecules having a suitable splicing activity, or by spliceosomes or splicing factors. The various splicing factors and spliceosomes are well known in the art, and this activity is generally described by Bruziket al., 1992,Nature 360, 692, hereby incorporated by reference herein. The invention concerns splicing of target nucleic acid molecules and Tag sequence which are not normally spliced together within a cell as described by Bruzik et al., supra. Rather, as described above, a Tag sequence is selected such that a useful function can be achieved in a gene therapeutic fashion.
- Generally, the reaction involves base pairing of the catalytic nucleic acid molecule with the targeted transcript, cleavage of the targeted transcript, and then ligation of the3′ exon (Tag sequence) with this targeted 5′ exon. The catalytic nucleic acid is removed in the reaction. As will be noted, the specificity of the reaction can be changed by alteration of the substrate binding site in the catalytic nucleic acid molecule by methods well known in the art.
- Optimizing Ribozyme Activity:
- Catalytic activity of the ribozymes described in the instant invention can be optimized as known in the art. The details will not be repeated here, but include altering the length of the ribozyme binding arms, or chemically synthesizing ribozymes with modifications (base, sugar and/or phosphate) that prevent their degradation by serum ribonucleases and/or enhance their enzymatic activity (see e.g., Eckstein et al., International Publication No. WO 92/07065; Perrault et al., 1990Nature 344, 565; Pieken et al., 1991 Science 253, 314; Usman and Cedergren, 1992 Trends in Biochem. Sci. 17, 334; Usman et al., International Publication No. WO 93/15187; and Rossi et al., International Publication No. WO 91/03162; Sproat, U.S. Pat. No. 5,334,711; and Burgin et al., supra; all of these describe various chemical modifications that can be made to the base, phosphate and/or sugar moieties of enzymatic RNA molecules). Modifications which enhance their efficacy in cells, and removal of bases from stem loop structures to shorten RNA synthesis times and reduce chemical requirements are desired. (All these publications are hereby incorporated by reference herein).
- There are several examples in the art describing sugar and phosphate modifications that can be introduced into enzymatic nucleic acid molecules without significantly effecting catalysis and with significant enhancement in their nuclease stability and efficacy. Ribozymes are modified to enhance stability and/or enhance catalytic activity by modification with nuclease resistant groups, for example, 2′-amino, 2′-C-allyl, 2′-flouro, 2′-O-methyl, 2′-H, nucleotide base modifications (for a review see Usman and Cedergren, 1992TIBS 17, 34; Usman et al., 1994 Nucleic Acids Symp. Ser. 31, 163; Burgin et al., 1996 Biochemistry 35, 14090). Sugar modification of enzymatic nucleic acid molecules have been extensively described in the art (see Eckstein et al., International Publication PCT No. WO 92/07065; Perrault et al. Nature 1990, 344, 565-568; Pieken et al. Science 1991, 253, 314-317; Usman and Cedergren, Trends in Biochem. Sci. 1992, 17, 334-339; Usman et al. International Publication PCT No. WO 93/15187; Sproat, U.S. Pat. No. 5,334,711 and Beigelman et al., 1995 J. Biol. Chem. 270, 25702; all of the references are hereby incorporated in their totality by reference herein). Such publications describe general methods and strategies to determine the location of incorporation of sugar, base and/or phosphate modifications and the like into ribozymes without inhibiting catalysis, and are incorporated by reference herein. In view of such teachings, similar modifications can be used as described herein to modify the nucleic acid catalysts of the instant invention.
- Nucleic acid catalysts having chemical modifications which maintain or enhance enzymatic activity are provided. Such nucleic acid is also generally more resistant to nucleases than unmodified nucleic acid. Thus, in a cell and/or in vivo the activity may not be significantly lowered. As exemplified herein such ribozymes are useful in a cell and/or in vivo even if activity over all is reduced 10 fold (Burgin et al., 1996,Biochemistry, 35, 14090). Such ribozymes herein are said to “maintain” the enzymatic activity on all RNA ribozyme.
- Therapeutic ribozymes delivered exogenously must optimally be stable within cells until translation of the target RNA has been inhibited long enough to reduce the levels of the undesirable protein. This period of time varies between hours to days depending upon the disease state. Clearly, ribozymes must be resistant to nucleases in order to function as effective intracellular therapeutic agents. Improvements in the chemical synthesis of RNA (Wincott et al., 1995Nucleic Acids Res. 23, 2677; incorporated by reference herein) have expanded the ability to modify ribozymes by introducing nucleotide modifications to enhance their nuclease stability as described above.
- A “nucleotide” as used herein is as recognized in the art to include natural bases (standard), and modified bases well known in the art. Such bases are generally located at the 1′ position of a sugar moiety. Nucleotide generally comprise a base, sugar and a phosphate group. The nucleotides can be unmodified or modified at the sugar, phosphate and/or base moiety, (also referred to interchangeably as nucleotide analogs, modified nucleotides, non-natural nucleotides, non-standard nucleotides and other; see for example, Usman and McSwiggen, supra; Eckstein et al., International PCT Publication No. WO 92/07065; Usman et al., International PCT Publication No. WO 93/15187; all hereby incorporated by reference herein). There are several examples of modified nucleic acid bases known in the art and has recently been summarized by Limbach et al., 1994,Nucleic Acids Res. 22, 2183. Some of the non-limiting examples of base modifications that can be introduced into enzymatic nucleic acids without significantly effecting their catalytic activity include, inosine, purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2,4,6-trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidines (e.g., 5-methylcytidine), 5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g. 6-methyluridine) and others (Burgin et al., 1996, Biochemistry, 35, 14090). By “modified bases” in this aspect is meant nucleotide bases other than adenine, guanine, cytosine and uracil at 1′ position or their equivalents; such bases may be used within the catalytic core of the enzyme and/or in the substrate-binding regions.
- By “unmodified nucleoside” is meant one of the bases adenine, cytosine, guanine, uracil joined to the 1′ carbon of b-D-ribo-furanose.
- By “modified nucleoside” is meant any nucleotide base which contains a modification in the chemical structure of an unmodified nucleotide base, sugar and/or phosphate.
- Various modifications to ribozyme structure can be made to enhance the utility of ribozymes. Such modifications will enhance shelf-life, half-life in vitro, stability, and ease of introduction of such ribozymes to the target site, e.g., to enhance penetration of cellular membranes, and confer the ability to recognize and bind to targeted cells.
- Administration of Trans-Splicing Nucleic Acid Molecules:
- Sullivan et al., PCT WO 94/02595, describes the general methods for delivery of nucleic acid molecules. For example, ribozymes may be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. For some indications, ribozymes may be directly delivered ex vivo to cells or tissues with or without the aforementioned vehicles. Alternatively, the RNA/vehicle combination is locally delivered by direct injection or by use of a catheter, infusion pump or stent. Other routes of delivery include, but are not limited to, intravascular, intramuscular, subcutaneous or joint injection, aerosol inhalation, oral (tablet or pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal delivery. More detailed descriptions of ribozyme delivery and administration are provided in Sullivan et al., supra and Draper et al., PCT WO93/23569 which have been incorporated by reference herein.
- The molecules of the instant invention can be used as pharmaceutical agents. Pharmaceutical agents prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state in a patient.
- The negatively charged polynucleotides of the invention can be administered (e.g., RNA, DNA or protein) and introduced into a patient by any standard means, with or without stabilizers, buffers, and the like, to form a pharmaceutical composition. When it is desired to use a liposome delivery mechanism, standard protocols for formation of liposomes can be followed. The compositions of the present invention may also be formulated and used as tablets, capsules or elixirs for oral administration; suppositories for rectal administration; sterile solutions; suspensions for injectable administration; and the like.
- The present invention also includes pharmaceutically acceptable formulations of the compounds described. These formulations include salts of the above compounds, e.g., acid addition salts, for example, salts of hydrochloric, hydrobromic, acetic acid, and benzene sulfonic acid.
- A pharmacological composition or formulation refers to a composition or formulation in a form suitable for administration, e.g., systemic administration, into a cell or patient, preferably a human. Suitable forms, in part, depend upon the use or the route of entry, for example oral, transdermal, or by injection. Such forms should not prevent the composition or formulation to reach a target cell (i.e., a cell to which the negatively charged polymer is desired to be delivered to). For example, pharmacological compositions injected into the blood stream should be soluble. Other factors are known in the art, and include considerations such as toxicity and forms which prevent the composition or formulation from exerting its effect.
- By “systemic administration” is meant in vivo systemic absorption or accumulation of drugs in the blood stream followed by distribution throughout the entire body. Administration routes which lead to systemic absorption include, without limitations: intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary and intramuscular. Each of these administration routes expose the desired negatively charged polymers, e.g., nucleic acids, to an accessible diseased tissue. The rate of entry of a drug into the circulation has been shown to be a function of molecular weight or size. The use of a liposome or other drug carrier comprising the compounds of the instant invention can localize the drug, for example, in certain tissue types, such as the tissues of the reticular endothelial system (RES). A liposome formulation which can facilitate the association of drug with the surface of cells, such as, lymphocytes and macrophages is also useful. This approach may provide enhanced delivery of the drug to target cells by taking advantage of the specificity of macrophage and lymphocyte immune recognition of abnormal cells, such as the cancer cells.
- The invention also features the use of the a composition comprising surface-modified liposomes containing poly (ethylene glycol) lipids (PEG-modified, or long-circulating liposomes or stealth liposomes). These formulations offer an method for increasing the accumulation of drugs in target tissues. This class of drug carriers resists opsonization and elimination by the mononuclear phagocytic system (MPS or RES), thereby enabling longer blood circulation times and enhanced tissue exposure for the encapsulated drug (Lasic et al.Chem. Rev. 1995, 95, 2601-2627; Ishiwataet al., Chem. Pharm. Bull. 1995, 43, 1005-1011). Such liposomes have been shown to accumulate selectively in tumors, presumably by extravasation and capture in the neovascularized target tissues (Lasic et al., Science 1995, 267, 1275-1276; Oku et al., 1995, Biochim. Biophys. Acta, 1238, 86-90). The long-circulating liposomes enhance the pharmacokinetics and pharmacodynamics of DNA and RNA, particularly compared to conventional cationic liposomes which are known to accumulate in tissues of the MPS (Liu et al., J. Biol. Chem. 1995, 42, 24864-24870; Choi et al., International PCT Publication No. WO 96/10391; Ansell et al., International PCT Publication No. WO 96/10390; Holland et al., International PCT Publication No. WO 96/10392; all of these are incorporated by reference herein). Long-circulating liposomes are also likely to protect drugs from nuclease degradation to a greater extent compared to cationic liposomes, based on their ability to avoid accumulation in metabolically aggressive MPS tissues such as the liver and spleen. All of these references are incorporated by reference herein.
- The present invention also includes compositions prepared for storage or administration which include a pharmaceutically effective amount of the desired compounds in a pharmaceutically acceptable carrier or diluent. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, inRemington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985) hereby incorporated by reference herein. For example, preservatives, stabilizers, dyes and flavoring agents may be provided. Id. at 1449. These include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. In addition, antioxidants and suspending agents may be used. Id.
- A pharmaceutically effective dose is that dose required to prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state. The pharmaceutically effective dose depends on the type of disease, the composition used, the route of administration, the type of mammal being treated, the physical characteristics of the specific mammal under consideration, concurrent medication, and other factors which those skilled in the medical arts will recognize. Generally, an amount between 0.1 mg/kg and 100 mg/kg body weight/day of active ingredients is administered dependent upon potency of the negatively charged polymer.
- Alternatively, the trans-splicing nucleic acid molecules of the instant invention can be expressed within cells from eukaryotic promoters (e.g., Izant and Weintraub, 1985Science 229, 345; McGarry and Lindquist, 1986 Proc. Natl. Acad. Sci. USA 83, 399; Scanlon et al., 1991, Proc. Natl. Acad. Sci USA, 88, 10591-5; Kashani-Sabet et al., 1992 Antisense Res. Dev., 2, 3-15; Dropulic et al., 1992 J. Virol, 66, 1432-41; Weerasinghe et al., 1991 J. Virol, 65, 5531-4; Ojwang et al., 1992 Proc. Natl. Acad. Sci. USA 89, 10802-6; Chen et al., 1992 Nucleic Acids Res., 20, 4581-9; Sarver et al., 1990 Science 247, 1222-1225; Thompson et al., 1995 Nucleic Acids Res. 23, 2259; Good et al., 1997, Gene Therapy, 4, 45; all of the references are hereby incorporated in their totality by reference herein). Those skilled in the art realize that any nucleic acid can be expressed in eukaryotic cells from the appropriate DNA/RNA vector. The activity of such nucleic acids can be augmented by their release from the primary transcript by a ribozyme (Draper et al., PCT WO 93/23569, and Sullivan et al., PCT WO 94/02595; Ohkawa et al., 1992 Nucleic Acids Symp. Ser., 27, 15-6; Taira et al., 1991, Nucleic Acids Res., 19, 5125-30; Ventura et al., 1993 Nucleic Acids Res., 21, 3249-55; Chowrira et al., 1994 J. Biol. Chem. 269, 25856; all of the references are hereby incorporated in their totality by reference herein).
- Trans-splicing nucleic acid molecules that cleave target molecules are expressed from transcription units (see for example Couture et al., 1996,TIG., 12, 510) inserted into DNA or RNA vectors. The recombinant vectors are preferably DNA plasmids or viral vectors. Ribozyme expressing viral vectors could be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. Preferably, the recombinant vectors capable of expressing the ribozymes are delivered as described above, and persist in target cells. Alternatively, viral vectors may be used that provide for transient expression of ribozymes. Such vectors might be repeatedly administered as necessary. Once expressed, the ribozymes cleave the target MRNA. The active ribozyme contains an enzymatic center or core equivalent to those in the examples, and binding arms able to bind target nucleic acid molecules such that cleavage at the target site occurs. Other sequences may be present which do not interfere with such cleavage. Delivery of ribozyme expressing vectors could be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from the patient followed by reintroduction into the patient, or by any other means that would allow for introduction into the desired target cell (for a review see Couture et al., 1996, TIG., 12,510).
- An expression vector comprising nucleic acid sequence encoding at least one of the trans-splicing nucleic acid molecules, such as a ribozyme, of the instant invention is disclosed. The nucleic acid sequence encoding the nucleic acid catalyst of the instant invention is operable linked in a manner which allows expression of that nucleic acid molecule.
- Also, featured is an expression vector compriseing: a transcription initiation region (e.g., eukaryotic pol I, II or III initiation region); b) a transcription termination region (e.g., eukaryotic pol I, II or III termination region); c) a gene encoding at least one of the nucleic acid catalyst of the instant invention; and wherein said gene is operably linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. The vector may optionally include an open reading frame (ORF) for a protein operably linked on the 5′ side or the 3′-side of the gene encoding the nucleic acid catalyst of the invention; and/or an intron (intervening sequences).
- Transcription of the trans-splicing construct sequences are driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters will be expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type will depend on the nature of the gene regulatory sequences (enhancers, silencers, etc.) present nearby. Prokaryotic RNA polymerase promoters are also used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells (Elroy-Stein and Moss, 1990Proc. Natl. Acad. Sci. USA, 87, 6743-7; Gao and Huang 1993 Nucleic Acids Res., 21, 2867-72; Lieber et al., 1993 Methods Enzymol., 217, 47-66; Zhou et al., 1990 Mol. Cell. Biol., 10, 4529-37). Several investigators have demonstrated that ribozymes expressed from such promoters can function in mammalian cells (e.g. Kashani-Sabet et al., 1992 Antisense Res. Dev., 2, 3-15; Ojwang et al., 1992 Proc. Natl. Acad. Sci. USA, 89, 10802-6; Chen et al., 1992 Nucleic Acids Res., 20, 4581-9; Yu et al., 1993 Proc. Natl. Acad. Sci. USA, 90, 6340-4; L'Huillier et al., 1992 EMBO J. 11, 4411-8; Lisziewicz et al., 1993 Proc. Natl. Acad. Sci. U.S.A., 90, 8000-4; Thompson et al., 1995 Nucleic Acids Res. 23, 2259; Sullenger & Cech, 1993, Science, 262, 1566). More specifically, transcription units such as the ones derived from genes encoding U6 small nuclear (snRNA), transfer RNA (tRNA) and adenovirus VA RNA are useful in generating high concentrations of desired RNA molecules such as ribozymes in cells (Thompson et al., supra; Couture and Stinchcomb, 1996, supra; Noonberg et al., 1994, Nucleic Acid Res., 22, 2830; Noonberg et al., U.S. Pat. No. 5,624,803; Good et al., 1997, Gene Ther. 4, 45; Beigelman et al., International PCT Publication No. WO 96/18736; all of these publications are incorporated by reference herein. The above ribozyme transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated virus vectors), or viral RNA vectors (such as retroviral or alphavirus vectors) (for a review see Couture and Stinchcomb, 1996, supra).
- Applicant also discloses an expression vector comprising nucleic acid sequence encoding at least one of the nucleic acid molecule of the invention, in a manner which allows expression of that nucleic acid molecule. The expression vector comprises in one embodiment; a) a transcription initiation region; b) a transcription termination region; c) a gene encoding at least one said nucleic acid molecule; and wherein said gene is operably linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. In another preferred embodiment the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an open reading frame; d) a gene encoding at least one said nucleic acid molecule, wherein said gene is operably linked to the 3′-end of said open reading frame; and wherein said gene is operably linked to said initiation region, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. In yet another embodiment the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) a gene encoding at least one said nucleic acid molecule; and wherein said gene is operably linked to said initiation region, said intron and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. In another embodiment, the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) an open reading frame; e) a gene encoding at least one said nucleic acid molecule, wherein said gene is operably linked to the 3′-end of said open reading frame; and wherein said gene is operably linked to said initiation region, said intron, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.
- The following is an example of various ribozyme constructs used to show the operability of the claimed invention. Those in the art will recognize that this example indicates the utility of the invention for both in vitro and in vivo splicing reactions. While significant utility will be attained in vivo by use of the present invention, those in the art will also recognize that in vitro utility is important and can be used to create chimeric transcripts for use in laboratory situations or in a clinical setting.
- Methods:
- Generation of RBC precursors from normal umbilical cord blood and from peripheral blood of sickle cell patients. Umbilical cord blood samples were obtained from labor and delivery and peripheral blood samples were obtained from sickle cell patients with hemoglobin SC disease undergoing scheduled phlebotomy. Mononuclear cells were isolated by ficol-hypaque gradient separation and resuspended at 1×106 cells/ml in BIT 9500 serum free media (Stem Cells Technology), supplemented with Flt-3 ligand (25 ng/ml, Immunex), IL-3 (2.5 ng/ml, R&D Inc.), and Erythropoeitin (1 u/ml, R&D Inc.). These cells were then cultured at 37° C. overnight and transferred to fresh plates to eliminate adherent cells.
- Transfection of RBC precursors. RBC precursors (1×106) were resuspended in Opti-MEM (200 ml, Gibco-BRL), and ribozymes (2.5-5 mg) were lipofected into these cells using DMRIE-C (20 ml, Gibco-BRL) in Iml Opti-MEM for four hours. Then, DMEM (Gibco-BRL) with 10% fetal calf serum (1 ml) and erythropoeitin (2 u/ml) were added to the cells. Total RNA was isolated using TRI Reagent (Molecular Research Center) 16-24 hours after transfection. Transfection of these cells with a reporter RNA demonstrated that 1-2% of the erythrocyte precursors take up RNA.
- Generation of the mapping library. The mapping library was generated by PCR amplification of the plasmid pT7L-21 with a 5′ primer containing a randomized sequence at the positions corresponding to the ribozyme's IGS (5′-GGGGGGATCCTAATACGACTCACTATAGNNNNNAAAAGTTATCA
- GGCATGCACC) and a 3′ primer specific for3′ exon tag sequences present in the pT7L-21 plasmid
- (5′-AGTAGTCTTACTGCAGGGGCCTCTTCGCTATTACG). The resulting cDNA library was in vitro transcribed using T7 RNA polymerase to generate the RNA mapping library.
- Trans-splicing reactions. Ribozyme-3′ exon (100-500 μM) and substrate RNAs (1-5 mM or 1 μg cellular RNA) were denatured at 95° C. for 1 min in reaction buffer (50 mM HEPES pH7.0, 150 mM NaCl and 5 mM MgCl2) and then equilibrated at 37° C. for 3 min. The substrates were then added to the ribozymes along with guanosine (100 mM) to start the reactions, which proceeded at 37° C. for 3 hours. For reactions containing radiolabeled ribozyme, aliquots were removed at the times indicated and added to an equal volume of EDTA (10 mM) to stop the reaction. Reaction products were analyzed on a 4% polyacrylamide gel containing urea (8M).
- RT-PCR analysis. Trans-splicing products were reverse-transcribed at 37° C. for 20 minutes in the presence of L-argininamide (10 mM) from a primer specific for the 3′ exon sequence as previously described. The resulting cDNAs were amplified for 30 cycles (in vitro ribozyme reactions) or 30-90 cycles (in vivo ribozyme reactions) using a 3′ exon primer (3′ tag primer: 5′-ATGCCTGCAGGTCGACTC, 3′gamma-globin primer: 5′-CCGGAATTCCCTTGTCCTCCTCTGTGA) and a 5′ primer specific for the beta-globin mRNA (5′GGGGATCCCTGTGTTCACTAGCAACC). The amplified products were separated on a 3% agarose gel and visualized by ethidium bromide staining.
- To ascertain which regions of the beta-globin transcript are accessible to ribozymes, we developed a novel RNA mapping strategy that employs a trans-splicing ribozyme library and RNA tagging. To generate the mapping library, the guide sequence of the Tetrahymena group I trans-splicing ribozyme was randomized such that the 5′ end of the RNAs in the library begin with 5′-GNNNNN-3′ where “G” represents guanine and “N” represents equal amounts of the 4 nucleotides15 (FIG. 3a). To map the beta-globin transcript in vitro, the mapping library was incubated with total RNA isolated from erythrocyte precursors under splicing conditions. To identify accessible uridine residues, the trans-splicing reaction products were reverse transcribed (RT) and amplified by the polymerase chain reaction (PCR) using primers specific for the ribozyme's 3′ exon tag6 and for the beta-globin target RNA (FIG. 3a). The resulting cDNAs were then sequenced to determine which uridine residues were present at the ribozyme reaction sites. From such analysis, the uridine at
position 61 of beta-globin RNA appears particularly accessible because 5 out of 9 sequenced clones contain splice junctions at this nucleotide (FIG. 3b). To determine which nucleotides are accessible on beta-globin transcripts inside cells, the mapping library was transfected into erythrocyte precursors. Total RNA was isolated from these cells and reactive uridines identified by RT-PCR amplification and sequence analysis. The uridine atposition 61 also appears to be particularly accessible in vivo because in 5 of the 9 clones examined the 3′ exon tag had been spliced onto this nucleotide (FIG. 3b). These mapping results, taken together with the fact that sickle beta-globin transcripts contain a point mutation atposition 70, encouraged applicant to focus on developing ribozymes that recognize the uridine present atposition 61 on the beta-globin MRNA. Thus, the internal guide sequence on the L-21 trans-splicing ribozyme was changed to 5′-GGGUGC-3′ to generate a ribozyme, called Rib61, specific forsite 61. In addition, an inactive version of this ribozyme, called Rib61d, which lacks part of the catalytic core of the enzyme was generated to control for the importance of ribozyme activity in these studies. - Rib61 can trans-splice a3′ exon tag onto beta-globin transcripts in vitro and in erythrocyte precursors (FIG. 4). The trans-splicing ribozymes, Rib61-3′tag and Rib61d-3′tag, were incubated under splicing conditions with βS-globin RNA generated by in vitro transcription or total RNA isolated from erythrocyte precursors. To determine if trans-splicing had occurred in any of the RNA samples, RT-PCR analyses were performed using one primer specific for the beta-globin target RNA and the other primer specific for the3′ exon tag sequence (FIG. 4a). An amplified fragment of the expected size (93 base pairs) was generated from samples containing Rib61-3′tag and either in vitro transcribed βS-globin RNA or total RNA isolated from sickle cell patient and UCB derived RBC precursors. No such RT-PCR product was generated from samples that lack a ribozyme or that contain the inactive version of the ribozyme.
- Sickle cell anemia is the most common heritable hematological disease yet no curative treatment exists for this disorder. Moreover the intricacies of globin gene expression have made the development of gene therapy based treatments for hemaglobinopathies difficult. Applicant describes an alternative genetic approach to sickle cell therapy. A trans-splicing group I ribozyme can be employed to amend mutant beta-globin transcripts in erythroid lineage cells. To determine which regions of the beta-globin transcript are accessible to ribozymes inside cells, a novel RNA mapping strategy was developed that employs a trans-splicing ribozyme library and RNA tagging From such analysis, the uridine at
position 61 of beta-globin RNA appears particularly accessible. A trans-splicing ribozyme that recognizes this nucleotide reacts with beta-globin transcripts with high fidelity in erythrocyte precursors derived from normal umbilical cord blood or peripheral blood from individuals with sickle cell disease. Moreover such splicing can convert sickle beta -globin transcripts into RNAs encoding the anti-sickling protein gamma-globin. These results suggest that trans-splicing ribozymes may represent a new approach to the treatment of sickle cell and other genetic diseases. - To determine if trans-splicing could be employed to repair mutant transcripts associated with a common genetic disorder, applicant tested whether such splicing ribozymes could amend mutant P-globin transcripts in erythroid lineage cells derived from the peripheral blood of patients with sickle cell disease (FIG. 2A). More specifically, we wanted to determine if splicing ribozymes could convert sickle β-globin (βS-globin) transcripts into RNAs encoding g-globin because fetal hemoglobin (Hb F) which contains γ-globin has been shown to greatly impede polymerization of hemoglobin S (Hb S). In this splicing reaction, the ribozyme recognizes the sickle beta-globin transcript by base pairing to an accessible region of the RNA upstream of the mutant nucleotide via an internal guide sequence (IGS), cleaves the βS-globin RNA, releases the mutation containing cleavage product and splices on the revised sequence for the globin transcript (FIG. 2A).
- To determine if trans-splicing ribozymes can react with beta-globin transcripts in clinically relevant cells, we generated erythrocyte precursors from normal umbilical cord blood (UCB) and from peripheral blood from patients with sickle cell disease by culturing the blood cells in serum free conditions supplemented with erythropoietin, Flt-3 ligand and IL-3. Nucleated red blood cells (RBC) appear by
day 7 under these culture conditions and by three weeks they constitute 70-90% of the total number of cells in the culture as evidenced by Wright-Giemsa and immunofluorescent staining (FIG. 2). Moreover because the majority of these erythroid lineage cells are late RBC precursors (FIG. 2), they are rich in globin transcripts making them ideal for the RNA repair studies described herein. - To determine if Rib61-3′tag could react with beta-globin transcripts inside primary human cells, the ribozyme was transfected into erythrocyte precursors derived from UCB and sickle cell patients. Total RNA was isolated from these cells and analyzed via RT-PCR to determine if trans-splicing products were present in any of the cellular samples (FIG. 4b). An amplified fragment of the expected size (93 base pairs) was generated from the RNA samples isolated from sickle cell patient and UCB derived RBC precursors that had been transfected with the active ribozyme. By contrast no such product was generated from RNA samples isolated from cells that were not transfected or were transfected with the inactive ribozyme. To determine if transsplicing was occurring during RNA isolation and analysis, Rib61-3′Tag was added to the RNA extraction buffer used to isolate total RNA from a sample of mock transfected erythrocyte precursors. No amplification product was generated when this “mixed” RNA sample was analyzed by RT-PCR (FIG. 4b) suggesting that the observed trans-splicing products were generated inside the RBC precursors and not during RNA analysis.
- Trans-splicing nucleic acid molecules can be employed to correct a broad array of mutant transcripts associated with a variety of genetic disorders. Here we demonstrate that a ribozyme can amend a disease related transcript, mutant β-globin mRNA, in clinically relevant cells, erythrocyte precursors derived from sickle cell patients. RNA repair may be a particularly appropriate genetic approach with which to treat sickle cell disease because the process should restore the regulated expression of anti-sickling versions of β-globin and simultaneously reduce the production of βS-globin (FIG. 2). Moreover, the efficiency of β-globin RNA repair will likely not have to be 100% to benefit patients. Sickle cell trait is a benign condition that is not associated with increased morbidity or mortality and sickle cell patients that express γ-globin at 10-20% the level of βS-globin in the majority of their RBCs have greatly improved clinical prognoses. The results presented here suggest that ribozyme-mediated repair of mutant RNAs may prove to be a useful approach to treat sickle cell disease and other inherited disorders.
- The trans-splicing reaction to repair mutant beta-globin transcript can be tested in vivo using a variety of sickle cell disease animal models, prior to testing in humans (for e.g., see Ryan et al., 1997,Science 278, 873; Paszty et al., 1997, Science. 278,876; both are incorporated by reference herein).
- To create a trans-splicing ribozyme that could convert βS-globin transcripts into RNAs encoding γ-globin (FIG. 2B), the3′ exon on Rib61-3′tag was changed to contain the human γ-globin cDNA sequence (nucleotides 29-545). This trans-splicing ribozyme, called Rib61-3′γ, can quickly and accurately trans-splice its 3′γ-globin exon onto βS-globin RNAs in vitro. Radiolabeled Rib61-3′γwas allowed to react with an excess of unlabeled full length (βS-FL) or truncated (βS-61) βS-globin substrate RNA (FIG. 5). In both reactions, Rib61-3′γ was quickly converted to free ribozyme (Rib) plus ligated globin exons (βS-61-3′γ) with an approximate half-time (t½) of 60 minutes. Rib61-3′γ reacted even faster (t½˜25 minutes) with a short 13 nucleotide substrate (5′SA5). The inactive version of the ribozyme (Rib61d-3′γ) was unable to mediate this splicing reaction (data not shown).
- To determine if this trans-splicing ribozyme could convert “authentic” βS-globin transcripts into RNAs encoding γ-globin, we transfected Rib61-3′γ into erythirocyte precursors derived from sickle cell patients and UCB. Total RNA was harvested from these cells and RT-PCR analyses were performed to determine if amended β-globin transcripts were present in the RNA samples (FIG. 5). An amplified fragment of the expected size (62 base pairs) was generated from RNA samples isolated from erythrocyte precursors derived from sickle cell patients or UCB that had been transfected with the active ribozyme, Rib61-3′. No such product was generated from RNA samples isolated from cells that were not transfected or were transfected with the inactive ribozyme. Moreover, no amplification product was generated from RNA samples in which Rib61-3′ was added to the RNA extraction buffer prior to lysing the mock transfected cells (FIG. 5). Thus the amended globin RNAs were almost assuredly generated by the trans-splicing ribozyme inside the RBC precursors and not during RNA analysis.
- To confirm that the amplified DNA products were generated from globin transcripts that had been correctly spliced, we subcloned and sequenced the amplified fragments. Sequence analysis of eight different subclones derived from sickle cell patient samples demonstrated that in each case the ribozyme had correctly spliced its γ-
globin 3′exon ontonucleotide 61 of the β-globin target transcript and in the process maintained the open reading frame for the translation of the MRNA. Thus, trans-splicing ribozymes appear to be able to revise mutant globin transcripts in primary human RBC precursors with high fidelity. - Uses
- Gene mapping and human genome sequencing provides the genetic basis for an increasing number of inherited diseases. With each discovery or identification of a new disease-related gene there is an opportunity to develop gene therapy based treatments.
- Trans-splicing nucleic acid molecules can be used to correct the defective transcripts issuing from mutant genes. This approach will be valuable for the treatment of the many genetic diseases caused by a common set of specific mutations which do not affect the expression of the mutant gene. For example, the genetic basis of many globin diseases is well understood. Targeted trans-splicing can repair or correct globin transcripts that are either truncated or contain point mutations. In the process, the cellular expression pattern of these genes is maintained. Therefore, targeted trans-splicing represents an important, novel strategy for the treatment of many genetic diseases.
- As noted above, trans-splicing may also be accomplished without the use of ribozymes. It has been demonstrated that spliced leader sequences from lower eucaryotes can be trans-spliced onto mammalian3′ splice sites in tissue culture cells (Bruzik et al.,Nature 360, 692 (1992)). Trans-splicing in this case is mediated by the spliceosome or splicing factors. There are several reports of protein dependent trans-splicing reactions in a variety of systems (see for example Ghetti et al., 1995, Proc. Natl. Acad. Sci., 92, 11461; Bruzik et al., supra). Thus, it is possible to employ spliceosomes to alter the sequence of targeted transcripts for some desired end via targeted trans-splicing.
- Trans-splicing nucleic acid molecules can be used to attach any Tag to a target nucleic acid molecules. The molecular Tags do not have to be composed of nucleic acid sequence. One can simply alter the molecular composition of the Tag attached to the ribozyme. Just as in vitro selection has allowed for the generation of novel ribozymes with new activities, similar selection should allow for the development of ribozymes that can covalently attach novel Tags to target molecules. Thus ribozymes can be developed that can covalently modify a range of target molecules in a variety of ways. Such ribozymes can be used for a number of diagnostics and in manufacturing applications. For example, if one wants to a make a soap that has a specific type of chemical linkage that is difficult to generate by classical organic chemistry techniques, now one can consider the generation of a ribozyme that will recognize the precursor of the final soap product, say a certain lipid, catalytically react with the lipid and covalently transfer a molecular group (the Tag in this case) to the target lipid to modify it in the desired manner. Thus, the ability of ribozymes to covalently attach molecules to specific substrate molecules may allows us to employ ribozyme in ways that were not previously envisioned. In another example, Tags such as biotin can be attached to a target nucleic acid molecule (e.g., a pathogenic virus RNA)in vitro using trans-splicing ribozymes in biological sample from a patient. The extent of biotin attachment to the target RNA can be used as a measure of viral load in the patient; such measurements can be made using standard techniques such as using avidin to isolate biotin tagged RNA from the sample and quantifying the biotin tagged RNA.
- Other embodiments are within the following claims.
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/205,520 US20030036517A1 (en) | 1997-12-05 | 1998-12-03 | Nucleic acid mediated rna tagging and rna revision |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6783497P | 1997-12-05 | 1997-12-05 | |
US09/205,520 US20030036517A1 (en) | 1997-12-05 | 1998-12-03 | Nucleic acid mediated rna tagging and rna revision |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030036517A1 true US20030036517A1 (en) | 2003-02-20 |
Family
ID=22078720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/205,520 Abandoned US20030036517A1 (en) | 1997-12-05 | 1998-12-03 | Nucleic acid mediated rna tagging and rna revision |
Country Status (6)
Country | Link |
---|---|
US (1) | US20030036517A1 (en) |
EP (1) | EP1036169A1 (en) |
JP (1) | JP2002506612A (en) |
AU (1) | AU1623499A (en) |
CA (1) | CA2312006A1 (en) |
WO (1) | WO1999029842A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050267058A1 (en) * | 2001-05-18 | 2005-12-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA) |
US8685937B2 (en) | 2008-08-09 | 2014-04-01 | University Of Iowa Research Foundation | Nucleic acid aptamers |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7034009B2 (en) | 1995-10-26 | 2006-04-25 | Sirna Therapeutics, Inc. | Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
US6482932B1 (en) | 1997-11-05 | 2002-11-19 | Ribozyme Pharmaceuticals, Incorporated | Nucleoside triphosphates and their incorporation into oligonucleotides |
US6617438B1 (en) | 1997-11-05 | 2003-09-09 | Sirna Therapeutics, Inc. | Oligoribonucleotides with enzymatic activity |
US6995259B1 (en) | 1998-10-23 | 2006-02-07 | Sirna Therapeutics, Inc. | Method for the chemical synthesis of oligonucleotides |
US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
WO2005041859A2 (en) | 2003-04-30 | 2005-05-12 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery. |
US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
EP1386004A4 (en) | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
EP1572067A4 (en) | 2001-05-18 | 2009-05-13 | Sirna Therapeutics Inc | Conjugates and compositions for cellular delivery |
US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US7205399B1 (en) | 2001-07-06 | 2007-04-17 | Sirna Therapeutics, Inc. | Methods and reagents for oligonucleotide synthesis |
US7071311B2 (en) | 2002-02-13 | 2006-07-04 | Sirna Therapeutics, Inc. | Antibodies having specificity for 2′-C-allyl nucleic acids |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
WO2008054561A2 (en) | 2006-07-11 | 2008-05-08 | University Of Medicine And Dentistry Of New Jersey | Proteins, nucleic acids encoding the same and associated methods of use |
AU2010334911A1 (en) | 2009-12-23 | 2012-07-12 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
EA030650B1 (en) | 2013-03-08 | 2018-09-28 | Новартис Аг | Lipids and lipid compositions for the delivery of active agents |
ES2908827T3 (en) | 2013-12-19 | 2022-05-04 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
JP6778175B2 (en) | 2014-07-16 | 2020-10-28 | ノバルティス アーゲー | Method of Encapsulating Nucleic Acid in Lipid Nanoparticle Host |
CN107072946B (en) | 2014-09-05 | 2022-01-11 | 诺华股份有限公司 | Lipids and lipid compositions for delivery of active agents |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5667969A (en) * | 1993-11-12 | 1997-09-16 | University Research Corporation | Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing |
-
1998
- 1998-12-03 CA CA002312006A patent/CA2312006A1/en not_active Abandoned
- 1998-12-03 AU AU16234/99A patent/AU1623499A/en not_active Abandoned
- 1998-12-03 WO PCT/US1998/025652 patent/WO1999029842A1/en not_active Application Discontinuation
- 1998-12-03 EP EP98960693A patent/EP1036169A1/en not_active Withdrawn
- 1998-12-03 JP JP2000524415A patent/JP2002506612A/en active Pending
- 1998-12-03 US US09/205,520 patent/US20030036517A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050267058A1 (en) * | 2001-05-18 | 2005-12-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA) |
US8685937B2 (en) | 2008-08-09 | 2014-04-01 | University Of Iowa Research Foundation | Nucleic acid aptamers |
Also Published As
Publication number | Publication date |
---|---|
CA2312006A1 (en) | 1999-06-17 |
WO1999029842A1 (en) | 1999-06-17 |
AU1623499A (en) | 1999-06-28 |
JP2002506612A (en) | 2002-03-05 |
EP1036169A1 (en) | 2000-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030036517A1 (en) | Nucleic acid mediated rna tagging and rna revision | |
AU750947C (en) | Nucleic acid catalysts with endonuclease activity | |
US5599706A (en) | Ribozymes targeted to apo(a) mRNA | |
US5646042A (en) | C-myb targeted ribozymes | |
US6057156A (en) | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors | |
US20020151693A1 (en) | Nucleic acid catalysts with endonuclease activity | |
US6448009B1 (en) | Method for target site selection and discovery | |
WO1998043993A2 (en) | Nucleic acid catalysts | |
US6103890A (en) | Enzymatic nucleic acids that cleave C-fos | |
WO1998032846A9 (en) | Enzymatic nucleic acid treatment of diseases or conditions related to levels of c-fos | |
CA2288640A1 (en) | Enzymatic nucleic acids: synthesis, selection and use | |
AU3974001A (en) | Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme | |
US5714383A (en) | Method and reagent for treating chronic myelogenous leukemia | |
CA2398750A1 (en) | Nucleozymes with endonuclease activity | |
AU757789B2 (en) | Method and reagents for the treatment of diseases or conditions related to molecules involved in angiogenic responses | |
US6656731B1 (en) | Nucleic acid catalysts with endonuclease activity | |
JP2002541795A (en) | Regulation of repressor genes using nucleic acid molecules | |
US20030144489A1 (en) | Method for screening nucleic acid catalysts | |
US20030064946A1 (en) | Method and reagent for the inhibition of calcium activated chloride channel-1 (CLCA-1) | |
US6280936B1 (en) | Method for screening nucleic acid catalysts | |
US6548657B1 (en) | Method for screening nucleic acid catalysts | |
RU2144080C1 (en) | Ribosime, method of inactivation of rna-target, method of ribosime preparing | |
WO2002011674A2 (en) | Method and reagent for the inhibition of calcium activated chloride channel-1 (clca-1) | |
CA2397813A1 (en) | Method and reagent for the inhibition of grid | |
MXPA97004726A (en) | Ribozimas varkud satell |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: RIBOZYME PHARMACEUTICALS, INC., COLORADO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SULLENGER, BRUCE A.;LAN, NING;LEE, SEONG-WOOK;AND OTHERS;REEL/FRAME:009820/0758;SIGNING DATES FROM 19990205 TO 19990302 |
|
AS | Assignment |
Owner name: DUKE UNIVERSITY, NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RIBOZYME PHARMACEUTICALS, INC.;REEL/FRAME:009927/0022 Effective date: 19990420 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:DUKE UNIVERSITY;REEL/FRAME:021176/0329 Effective date: 20010719 |